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Abstract 
Background. Substrate utilization for energy production is highly 
regulated during cardiac development, with the onset of cardiac 
hypertrophy and in the transition to heart failure. Glucose and lactate are 
the predominant fuel substrates utilised during cardiac development. 
Postnatally. a switch in energy substrate utilisation occurs. so that fatty 
acids become the chief energy substrate in the non-fed normal adult 
mammalian heart. However. with cardiac hypertrophy and failure. a 
transition reminiscent of foetal energy metabolism occurs with reduced 
fatty acid and increased glucose utilisation. Little is known. however. about 
the molecular regulatory mechanisms involved in this energy metabolic 
remodelling. nor whether this reversion towards foetal energy substrate 
utilisation contributes towards the development of cardiac hypertrophy 
and/or heart failure. Objectives. To begin to understand the role of this 
metabolic remodelling on cardiac development and disease we need to 
understand the regulatory mechanisms orchestrating these fluxes in 
substrate utilisation. Therefore, the focus of this dissertation addresses the 
study of mOlecular regulatory mechanisms directing these switches in 
energy substrate use, focussing on rate-controlling metabolic enzyme 
encoding genes during cardiac development and with the onset of cardiac 
hypertrophy and heart failure. The preparatory studies were on the gene 
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expression patterns of numerous genes encoding for rate-controlling 
enzymes required for fatty acid and glucose catabolism in cardiac 
development and hypertrophy. The predominant focus is on the regulatory 
control of a nuclear-encoded mitochondrial ~-oxidation enzyme gene 
responsible for medium-chain fatty acid catabolism in the heart during the 
development of cardiac hypertrophy and the transition to heart failure. 
Results. Coordinate regulation of genes encoding multiple metabolic 
enzymes required for fatty acid and glucose metabolism were 
demonstrated during both cardiac development and with the onset of 
cardiac hypertrophy. The fatty acid import and oxidation encoding enzyme 
gene expression patterns parallel the known utilization of fatty acids during 
cardiac development and with the onset of cardiac hypertrophy. In 
contrast, the adult-enriched glucose import and glycolytic enzyme 
encoding gene expression patterns are inversely regulated with respect to 
the known use of glucose with the development of cardiac hypertrophy . To 
further define these cardiac stage-specific gene expression patterns, we 
focused on the characterisation of the gene regulatory programme of 
medium chain acyl-CoA dehydrogenase, a representative mitochondrial 
fatty acid ~-oxidation (FAO) enzyme gene. We initially assessed medium 
chain acyl-CoA dehydrogenase regulation at the level of transcription, via 
induction of right ventricular hypertrophy (RVH) in mice transgenic for the 
human medium chain acyl-CoA dehydrogenase promoter fused to a CAT 
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reporter. Compared with sham controls, right ventricular medium chain 
acyl-CoA dehydrogenase and CAT mRNA levels were repressed by 
greater than 80% in the hypertrophied ventricles. Thus, the known 
reduction in FAO during the development of cardiac hypertrophy may be 
regulated in large part at the level of gene transcription. Using 
DNA:Protein interaction studies and gene promoter/reporter transfection 
studies, a number of putative nuclear regulatory proteins which 
orchestrate this regulation were identified. Interestingly, the repression of 
medium chain acyl-CoA dehydrogenase transcription with the 
development of pressure overload-induced cardiac hypertrophy appears 
to be via the reactivation of a foetal gene regulatory programme. The 
temporal pattern of this alteration in medium chain acyl-Co A 
dehydrogenase gene expression was then characterized in a rat model of 
progressive left ventricular hypertrophy (L VH) and heart failure (HF) 
[SHHF/Mcc-facp (SHHF) rat]. Medium chain acyl-CoA dehydrogenase 
enzyme mRNA level were down regulated (>70%) during both the L VH and 
HF stages in the SHHF rats compared with controls. In contrast, the 
activity and steady-state levels of the medium chain acyl-CoA 
dehydrogenase enzyme were not Significantly reduced until the HF stage, 
indicating additional control at the translational or post-translational 
regulatory levels in the hypertrophied but non-failing ventricle. To evaluate 
whether medium chain acyl-CoA dehydrogenase gene expression could 
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be modulated by attenuating the development of cardiac hypertrophy, we 
treated spontaneously hypertensive rats (SHR's) with the a- and ~­
adrenoreceptor antagonist, carvedilol. This therapy modestly attenuated 
the development of cardiac hypertrophy and significantly blunted the 
known downregulation of the metabolic gene expression pattern towards 
foetal levels in the treated SHR's compared to the placebo treated 
littermate controls. Finally. to determine whether this regulatory 
programme is applicable to human disease. medium chain acyl-CoA 
dehydrogenase protein and gene expression were delineated in the left 
ventricles of human cardiac transplant recipients. Medium chain acyl-CoA 
dehydrogenase enzyme and mRNA levels were coordinately 
downregulated (>40%) in failing human ventricles compared with controls. 
We have thus identified an energy metabolic gene regulatory programme 
that is regulated in part at the level of transcription during cardiac 
hypertrophy with additional translational or post-translational regulatory 
control. This translational/post-translational control is altered with the 
onset of heart failure and may contribute to the transition to this 
decompensated state. Conclusions. The medium chain acyl-CoA 
dehydrogenase gene regulatory control data elicited in this dissertation 
suggests a complex molecular regulatory programme directing metabolic 
remodelling during cardiac development. with the onset of cardiac 
hypertrophy. with the attenuation of hypertrophic growth in the heart and 
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following the onset of heart failure. Further delineation and 
characterisation of these regulatory events are required to increase our 
understanding of the role of metabolic remodelling in cardiac development 
and disease. Finally, we propose that the data presented in this body of 
work advances the understanding of cardiac metabolism to include 
regulation at the genomic level. 
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Glossary of Molecular Biologic Terminology: 
Cis elements: DNA sequences within an individual gene that are 
responsible for directing the level of expression of the same gene. 
Enhancer: Cis acting elements that can direct a significant increase in 
transcription independent of their respective position and orientation within 
a given gene; enhancers can play an important role in the regulation of 
tissue specific and inducible expression of individual gene. 
Gene: The entire DNA sequence necessary for the synthesis of a 
functional protein (polypeptide) or RNA sequence. 
Homology: DNA sequences appear partially identical when genes of 
different species are compared. It is estimated that the genes of mouse 
and man are 80% identical. which is considered high level of homology. 
Isoforms: Proteins with a similar structure and function. They can be 
derived from a single gene or physically separate genes. 
Knock-out: Gene targetting technique. to delete one allele of a gene 
through homologous recombination. The exact localization of this deletion 
is known. Lethality in homologous embryos indicates the essential function 
of the gene. 
Messenger RNA (mRNA): The final RNA molecule formed through 
precursor RNA splicing and modification of the ends (polyA tail). This is 
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the RNA molecule encompassing all coding sequences and capable of 
crossing the nuclear membrane to bring the message to the ribosomes for 
protein synthesis. 
Poly A: The polymer of adenine nucleotides that are located at the end of 
mRNA. 
Promoter: The region of a gene that binds RNA polymerase and initiates 
gene transcription; can include DNA elements that regulate various 
phases of development, target expression of a gene to selective tissues, 
and confer inducibility in response to defined stimuli. 
Phenotype: Observable characteristics of an organism, resulting from the 
interaction of its genes and the environment in which development occurs. 
Ribosomes: Consist of two unequal subunits bound together by 
magnesium ions. This cytosolic organelle translates mRNA into its 
appropriate protein. 
Trans acting factor: The regulatory factors not located in the gene itself but 
direct and regulate the expression of a given gene (e.g., proteins that bind 
and regulate the promoter region of a gene). 
Transcript: Product of transcription (RNA) 
Transcription: The synthesis of RNA from a DNA template by the protein 
RNA polymerase. 
17 
Transcription factor: Protein, that can modify transcription levels of a gene 
through direct binding of specific DNA sequences (cis-elements) of that 
gene. 
Transfection: Introduction of foreign DNA into eukaryotic cells. 
Transgenic: A technique used to transfer a gene into the germline of 
experimental animals that express the exogenous gene. The number of 
times and the localization of the transgene incorporation into the genome 
are unpredictable and random. 
Translation: The synthesis of proteins from the mRNA template by the 
ribosomes. 
18 
Abbreviations 
DW 
CAT 
CMP 
COUP-TF 
cTNI 
EMSA 
FAO 
GAPDH 
GLUT4 
HF 
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- Distilled Water 
- Chloramphenicol acetyltransferase 
- Cardiomyopathy 
- Chicken ovalbumin upstream promoter transcription factor 
- Cardiac troponin I 
- Electromobility shift assay 
- Mitochondrial fatty acid ~-oxidation 
- Glyceraldehyde-3-phosphate dehydrogenase 
- Insulin Sensitive Cardiac Enriched Glucose Transporter 
- Heart Failure 
- Long chain fatty acyl-CoA dehydrogenase 
- Long chain acyl-CoA synthetase 
- Left Ventricular Hypertorphy 
- Medium chain acyl-CoA dehydrogenase 
- Nuclear Receptor Response Element 
- Oxygen 
- Pulmonary Artery Banding 
- Peroxisome Proliferator Activated Receptor (a isoform) 
- Phosphofructokinase - Muscle enriched isoform. 
- Right Ventricular Hypertrophy 
SHHF 
SHR 
Sp1 
-Spontaneously Hypertensive - Heart Failure Rat -
SHHF/Mccfacp 
- Spontaneously Hypertensive Rat 
- Zinc finger nuclear regulatory protein acting as a 
transcriptional activator or repressor in a promoter specific 
context 
Sp3 - Zinc finger nuclear regulatory factor which usually acts to 
repress transcriptional gene activity 
WF - Wistar Furth Rat 
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Introduction 
Cardiac Hypertrophy and Heart Failure 
The development of ventricular hypertrophy constitutes one of the 
principal mechanisms by which the heart compensates for an increase in 
load.1 One of the earliest cellular changes that occurs after a hypertrophic 
stimulus is the synthesis of mitochondlia, presumably to provide the high-
energy phosphates required to meet the increased energy demands of the 
hypertrophied cells.2 The hypertrophied heart is usually considered to be 
a physiologically compensated state following an increased load on the 
heart. Compensated cardiac hypertrophy is associated with a proportional 
increase in the size of individual cardiac cells to maintain the systolic 
stress of the heart within normal Iimits.3 The concept of the compensated 
heart may, however. be misleading as cardiac hypertrophy is an 
independent risk factor for sudden cardiac death.4 
Heart failure is usually associated with progressive cardiac pump 
failure, with associated symptoms of dyspnoea and peripheral oedema. 
The pump failure may be from reduced contractility or an inability of the 
heart muscle to adequately relax between contractions. The underlying 
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pathologies are multiple. and the end result is most often that of 
accelerated death.5 
Hypothesis 
A contributory role of altered energy production in the development of 
cardiac hypertrophy and the transition to heart failure has been an 
attractive. yet elusive hypothesis to prove. Evidence supporting this 
hypothesis includes the phenotypic presentation of cardiac hypertrophy 
and/or heart failure in individuals with inherited defects in metabolic 
genes;6-9 and in some non-ischaemic diabetic patients (diabetic 
cardiomyopathy). 1 0 Moreover. the ablation of the genes encoding the 
adult cardiac enriched facilitative glucose transporter - (GLUT 4),11 and 
the gene encoding a putative intra-cytoplasmic heart specific fatty acid 
binding proten - (hFABP)12 result in the development of cardiac 
hypertrophy in mice. In combination. these data implicate altered energy 
substrate utilization as a contributory factor in the pathogenesis of non-
ichaemic cardiac hypertrophy and heart failure. 
Substrate use for energy production is highly regulated during 
cardiac development and with the onset of cardiac hypertrophy and 
transition to heart failure.13• 14 Glucose and lactate are the predominant 
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fuel substrates utilized during cardiac development. Postnatally, a switch 
in energy substrate utilization occurs, so that fatty acids are the chief 
energy substrate in the non-fed normal adult mammalian heart. However, 
with cardiac hypertrophy and failure, a transition reminiscent of foetal 
energy metabolism occurs with reduced fatty acid and increased glucose 
utilization.15, 16 Little is known, however, about the molecular regulatory 
mechanisms involved in this alteration in cardiac energy metabolism. Nor 
whether this reversion to the foetal energy substrate utilization contributes 
towards the development of cardiac hypertrophy and/or heart failure. 
The hypothesis studied is that the regulation of genes encoding 
rate-controlling enzymes in fatty acid and glucose utilization pathways 
during the development of cardiac hypertrophy and heart failure are due to 
the reactivation of foetal gene regulatory programmes. Moreover, to begin 
to understand whether these gene regulatory programmes direct the 
known switch in energy substrate utilisation in cardiac hypertrophy and 
heart failure, these gene regulatory programmes need to be studied. Thus 
the further delineation and characterization of the regulatory programmes 
directing a gene encoding a metabolic enzyme during cardiac 
development and with the onset of cardiac hypertrophy/failure was studied 
at the molecular level. 
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Energy Metabolism • A Perspective on the Focus of this Thesis 
Prior to summarizing the known changes in energy metabolism in cardiac 
development, cardiac hypertrophy and heart failure, I will define the focus 
of this body of work in the context of the broad field of cardiac metabolism. 
A diverse array of studies of "cardiac metabolism" have been undertaken 
as energy metabolism is an integral component of cardiac function. The 
importance of metabolism in cardiac function is illustrated by the fact that 
the human heart accounts for only 0.5% of the total body weight, yet it 
claims 10% of the body's 02 consumption.14 Metabolic investigations in 
the heart include the study of: energy fuel substrate uptake and utilisation; 
metabolic pathway enzymatic activities; high-energy phosphate 
metabolism; cardiac oxygen consumption and the conversion of chemical 
energy to mechanical energy (cardiac efficiency). In this thesis the 
emphasis is on the utilization of fuel substrates by the heart for the 
production of chemical energy for the subsequent maintenance of cardiac 
contractile function. Many factors contribute to the selection of energy 
providing fuels for cardiac energy production. Krebs et al17 classified 
these as: (i) the concentration of the direct fuel in the tissue, (ii) the 
presence in the tissue of the enzymes required for the degradation, and 
(iii) the kinetic properties of the key enzymes, especially those that initiate 
the release of energy. Each of these three main factors is, in turn, 
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complex and depends on a variety of components. In this thesis, the focus 
is on the regulation of genes encoding representative energy metabolic 
enzymes in the context of pressure overload-induced cardiac hypertrophy 
and the subsequent transition to non-ischaemic cardiomyopathy. Thus, 
this body of work focuses on the gene regulatory programmes of category 
(ii), namely, directing the presence in the heart of the enzymes required 
for fuel substrate catabolism. 
Fuel Substrate Utilization in Cardiac Development, Cardiac 
Hypertrophy and Heart Failure 
During cardiogenesis the heart functions in a relatively hypoxic 
environment and glucose and lactate are the predominant fuel 
substrates. 18, 19 Postnatally, a switch in energy substrate utilisation 
occurs, so that fatty acids become the predominant fuel substrate utilised 
in the fasted state.13 These switches in energy substrate utilisation for 
ATP production correspond to 02 availability. When 02 is rate-limiting, as 
in the foetal period, more ATP is generated from glucose and lactate per 
mole of O2 consumed than from fatty acid oxidation.14 Conversely, when 
there is an abundance of O2, the energy yield from the oxidation of long-
chain fatty acids is greater, on a mole-by-mole basis, than that obtained 
from glucose or lactate catabolism. Of note, this switch in energy substrate 
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utilisation is paralleled by mitochondrial development, the main 
intracellular organelle for oxidative phosphorylation of ADP. Full 
mitochondrial maturation is evident in the late foetal to early postnatal 
period20 and the postnatal heart is richly abundant in mitochondria, with 
the mitochondrial volume accounting for 25% of cardiocyte volume in 
humans to 38% in mice.21 
The utilization of energy substrate and metabolic pathway 
enzymatic activities that have been observed in animals and humans 
demonstrate that glucose metabolism is increased with concurrent 
reduced fatty acid utilization in association with acquired cardiac 
hypertrophy and heart failure. These changes parallel the metabolism of 
the foetal heart and suggest a reversion to foetal metabolism in these 
pathologic states. However, the molecular regulation of cardiac energy-
producing pathway enzymes during the development of cardiac 
hypertrophy and heart failure have not been previously studied. Moreover, 
characterisation of metabolic enzyme gene regulation during the 
development of compensated hypertrophy and in the decompensating 
failing heart may give us further inSight into the contribution of energy 
metabolism in these disease processes. 
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Genetic Defects in Energy Control and Cardiac Dysfunction 
Identification and subsequent characterization of inherited defects in 
genes encoding fuel substrate utilization enzymes should give us greater 
insight into the functional role of altered fuel substrate utilization in the 
development of cardiac hypertrophy and non-ischaemic cardiomyopathy. 
Familial analyses have shown that cardiomyopathy may have a genetic or 
inherited basis in children and adults. For example, approximately 20 
percent of patients with idiopathic dilated cardiomyopathy were found to 
have a first-degree relative with myocardial dysfunction.22 Many 
deSCriptions of individual kindreds with cardiomyopathy of unknown cause 
transmitted as autosomal dominant, autosomal recessive, and X-linked 
traits have appeared.23-25 Accordingly. a substantial proportion of 
idiopathic cardiomyopathies may have a genetic cause. 
Molecular geneticists have concentrated primarily on identifying 
single-gene disorders resulting in human disease. including numerous 
cardiomyopathic syndromes. Recently. Kelly et al7 reviewed the 
categories for which the genes causing cardiomyopathy have been 
identified (Table 1). Genetic defects have been predominantly identified in 
genes encoding cardiac contractile proteins. The characterization of the 
genetic defects resulting from the inherited defects in these contractile 
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protein encoding genes have been extensively reviewed ,26, 27, and will 
not be discussed further. 
However, a second subset of genetic disorders include defects in 
genes encoding enzymes required for mitochondrial oxidative 
phosphorylation and for mitochondrial fatty acid l3-oxidation. The majority 
of cardiomyopathy due to defects in mitochondrial oxidative 
phosphorylation are concurrent with neuromuscular defects or 
mitochondrial myopathies (Table 1). 
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Contractile/Structural 
Protein Gene Defects 
Defects have been 
identified ih genes encoding 
myosin heavy and light 
chain Isoforms, troponln 
I and C Isoforms, 
myosin binding protein C, and 
in ex tropomyosin 
The clinical features are 
variable, and Include: 
asymetrlcal septal hyper-
trophy, left ventricular 
hypertrophy, outflow tract 
obstruction. Sudden death Is 
relatively common. Some 
subjects, however, are 
asymptomatic with or without 
ventricular hypertrophy 
Disorders of 
Energy Metabolism 
Defects have been 
identified in genes encoding 
enzymes required for 
mitochondrial fatty acid uptake, 
~-oxldatlon and mitochondrial 
oxidative phosphorylation 
;-t" 
The clinical features of the 
fatty acid oxidation enzyme 
defects are variable, and ... 
include: cardiomyopathy, . 
fasting hypoglycemia, 
hepatic dysfunction and 
skeletal myopathies. 
The clinical features of 
disorders In mitochondrial 
oxidative phosphorylation 
include: neuromuscular 
manifestations and mitochondrial 
myopathies. Skeletal myopathy 
is more common than the 
cardiac variant . 
X-Linked Muscular 
Dystrophies 
Duchenne's and 
Becker's are the most 
common inherited skeletal 
myopathies. Defects have 
been identified in the gene 
encoding dystrophln, a large 
membrane associated 
protein in both syndromes. 
The clinical features of 
both Duchenne's and 
Becker's muscular dystophy 
are predominantly skeletal 
myopathy. Most patients, 
however, have evidence of 
cardiomyopathy. 
Table 1. Classification of inherited defects presenting with 
cardiomyopathy as a clinical feature. This classification is based on a 
review by Kelly et al,28 and summarizes the disorders. Disorders due to 
myocardial infiltration (e.g., glycogen storage diseases) are not reviewed. 
30 
Autosomal recessive defects in genes encoding multiple fatty acid ~­
oxidation enzymes cause cardiac hypertrophy, heart failure, and sudden 
death in human subjects.7 The most commonly inherited gene defect of 
the mitochondrial fatty acid ~-oxidation (FAO) enzyme encoding genes is 
that of medium chain acyl-CoA dehydrogenase (MCAD). The MCAD gene 
defect is an autosomal recessive inherited disorder, and cardiac 
phenotypic manifestations include cardiac hypertrophy and dilated 
cardiomyopathy.29 The inherited FAO enzyme defects which most 
commonly manifest with cardiomyopathy are defects in the genes 
encoding the enzymes required for long and very long chain fatty acid 
metabolism. Moreover, in a recent study screening subjects with 
hereditary hypertrophic cardiomyopathy, a high incidence of a deficiency 
of a putative long chain fatty acid transporter (CD36) was noted in the 
subset of subjects with asymmetrical hypertrophy of the cardiac septum. 
Furthermore, those individuals with deficiency in CD36 and asymmetrical 
septal hypertrophy also had decreased long chain fatty acid uptake into 
the hypertrophied myocardium despite normal myocardial perfusion.9 
These data suggest that in a subset of subjects with genetic defects 
disrupting fatty acid metabolic genes, the reduced capacity to utilize fatty 
acids for energy production, can directly result in cardiac contractile 
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dysfunction. However. whether a reduction in fatty acid utilization capacity, 
contributes to cardiac decompensation in acquired forms of heart disease 
is unknown. 
Acquired I Induced Defects in Fuel Substrate Utilisation and 
Myocardial Dysfunction 
Diabetes mellitus is the most common metabolic disease in which cardiac 
dysfunction may present as a distinct manifestation independent of 
coronary artery disease. Primarily, cardiac contractile dysfunction presents 
in diabetic patients in association with myocardial ischaemia. This 
combination of diabetes (hyperglycemia, elevated free fatty acids and 
ketone bodies) and myocardial ischaemia (hypoxia, lactic acidosis. fuel 
substrate limitations) has, not surprisingly. been recognized as resulting in 
a higher incidence of. and more pronounced myocardial cell death. 
contractile dysfunction and a worse prognosis compared to non-diabetics. 
To dissect out the functional significance of the metabolic pertubations in 
these circumstances. is very complex and not discussed further in this 
monograph. However. it has been determined that ventricular 
performance can be impaired (diabetic cardiomyopathy) in the presence of 
minimal, or in the absence of ischaemic heart disease in subjects with 
diabetes mellitus.10 Whether the reduced capacity to utilise glucose, the 
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elevated levels of circulating free fatty acids or the high myocardial 
triacylglycerol content in diabetes contribute to contractile dysfunction in 
these subjects is unknown. Molecular approaches to address these 
question are being pursued and are addressed briefly in the introductory 
section on the manipulation of metabolic enzyme encoding genes. 
Finally, the impairment of cardiac fatty acid utilization by 
pharmacologic inhibition of mitochondrial fatty acid importation in animal 
studies has been shown to result in the development of cardiac 
hypertrophy and contractile dysfunction. 30, 31 
Thus, cardiac dysfunction can be a manifestation of defective 
substrate utilization in humans (diabetes mellitus) and in animals 
subjected to pharmacologic inhibition of mitochondrial fatty acid import. 
Taken together these data suggest a fundamental role of substrate 
utilization in the induction of myocyte growth and dysfunction. 
Candidate Enzyme Encoding Genes Studied - An Overview of 
Metabolic Pathways 
The focus of this thesis is on the gene regulatory programmes directing 
the presence of cardiac rate-controlling enzymes required for major fuel 
substrate catabolism during cardiac development and with the onset of 
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cardiac hypertrophy. I will therefore, briefly review these energy metabolic 
pathways, concentrating on these key enzymes. 
During cardiogenesis the major fuel substrates are glucose 
(exogenous and intracellular glycogen) and lactate. Perinatally, in parallel 
with mitochondrial genesis the contribution of fatty acid oxidation is 
enhanced with reduced glucose and lactate utilisation. In the adult it has 
been well characterised that fatty acid oxidation accounts for between 60 
and 100% of oxygen consumption with a lesser contribution from lactate 
and glucose (0-20% of each).32 The switches and variability in substrate 
use are dependent in part on the nutritional status with increased glucose 
use in the acute post food-consumption period and predominantly fatty 
acid use during the greater part of the day. Moreover, switches in fuel 
substrate are also precipitated by acute increase in work load, when 
glycogen and glucose become preferentially oxidized in the heart.33 
Regulation of Glycolysis and Glycogen Metabolism 
The uptake of extracellular glucose is regulated by the transmembrane 
gradient and the concentration and activity of glucose transporters (See 
Figure 1) in the plasma membrane. Two isoforms from the glucose 
transporter family have been identified in the myocardium, GLUT1 and 
GLUT4.34, 35 Both transporters are located in the sarcolemmal 
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membrane and in intracellular microsomal vesicles36 and are regulated at 
the levels of gene transcription through post-translational control 37. 38. 
Upon entering the cell. free glucose is rapidly phosphorylated by 
hexokinase to form glucose-6-phosphate (G-6-P), which is impermeable to 
the cell membrane (Figure 1). G-6-P can be used for either glycogen 
synthesis or it can proceed down the glycolytic pathway to form pyruvate 
(Figure 1). 
35 
Cytoplasm 
Mitochondria 
Figure 1 
Fatty Acid 
Import 
LeAS 
Fatty Acid 
Thlooslerificalion 
Glucose Import 
LUT4 
PFK-M ~ 0 
GlycolysIs 
... 0 GP-B 
GAPDH 
Figure 1. Schematic Representation of the Major Cardiac Metabolic 
Pathways. 
The expression patterns of genes encoding the following substrate uptake 
and catabolism enzymes were assessed during cardiac development and 
with the onset of hypoxia induced RVH: (i) Long-chain acyl CoA 
synthetase (LCAS), a thioesterification enzyme that facilitates the transfer 
of long chain fatty acids across the cytosolic compartment; (ii) medium 
chain acyl-CoA dehydrogenase (MCAD), a representative enzyme in the 
mitochondrial fatty acid ~-oxidation cycle; (iii) GLUT 4, an adult cardiac 
enriched facilitative glucose transporter; (iv) the adult cardiac enriched 
isoform of phosphofructokinase (PFK-M); and the ubiquitous glycolytic 
enzyme - glyceraldehyde 3-P dehydrogenase (GAPDH). Additional 
abbreviations on figure: TCA - tricarboxylic acid, GS - glycogen synthase, 
GP-B - glycogen phosphorylase - brain isoform. 
37 
Understanding the regulation of cardiac glycogen metabolism is important 
as glycogen has been shown to account for up to 41 % of glucose 
metabolism and is preferentially oxidized compared with exogenous 
glucose in the adult heart under aerobic conditions.39, 40 Moreover, the 
role of glycogen during cardiogenesis is proposed to extend beyond 
metabolic requirements, and is potentially thought to play a role in 
mechanical cardiocyte stability.20, 41 The rate of glycogen synthesis is 
regulated by the concentration of G-6-P and the activity of glycogen 
synthase (GS). GS activity and glycogen storage are increased by 
insulin.42 Glycogenolysis results in the formation of G-6-P, and is 
regulated by the activity of glycogen phosphorylase (GP). GP activity is 
controlled by both hormonal stimulation (e.g. ~-adrenergic receptor 
stimulation) and via energy demand (contractile function).43 Animal and 
human studies indicate that there is simultaneous synthetase and 
phophorylase activities in-vivo.39, 44 In addition, the cardiac glycogen 
content is highly dependent on substrate availability, energy demand and 
on the species studied (Reviewed 43). 
The overall rates of glucose uptake, glycogen synthesis and 
breakdown, and the rate of glycolysis are controlled by multiple steps 
distributed along these pathways, and not subject to control at a discrete 
point.45 Given a constant supply of G-6-P, the primary regulators of 
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glycolytic rate are the activity of phosphofructokinase (PFK)(EC 2.7.1.11), 
and the ability to form reduced NADH.46 NAD+ is reduced to NADH by the 
conversion of glyceraldehyde 3- phosphate to 3-phosphoglycerol by the 
enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH). GAPDH, 
was thought to be a constitutively expressed, but now appears to be 
regulated by contractile work,47 during myocardial ischaemia48 and with 
the circadian rhythm.49 The final fuel product of the glycolytic pathway is 
the formation of pyruvate. Of note, lactate is an additional major in-vivo 
source of pyruvate formation in the heart. 50 
Pyruvate decarboxylation is the key irreversible step in 
carbohydrate oxidation and is catalysed by pyruvate dehydrogenase 
(PDH). Pyruvate oxidation and the activity of PDH in the heart are 
decreased by elevated rates of fatty acid oxidation and enhanced by the 
suppression of fatty acid oxidation. 
Glucose Utilisation Enzyme Isoforms 
Multiple isoforms of genes encoding rate-controlling glucose utilization 
enzymes have been described. The expression patterns of the respective 
isoforms are relatively tissue specific, thereby, directing the presence of 
these enzymes in an appropriate developmental and tissue specific 
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manner. The developmental expression patterns of gene isoforms 
encoding the representative rate-controlling glucose utilization enzymes 
used in this study are described in the results section of this dissertation. 
Two of the facilitative glucose transporters are known to be 
enriched in the heart, these include GLUT1 and GLUT4. GLUT1, the more 
ubiquitous isoform, is thought to be the major determinant of basal 
glucose transport in cardiac muscle. 51 GLUT1 is developmentally 
regulated in the heart with high mRNA expression in the foetus and 
reduced expression in the adult myocardium.52 GLUT4 is the 
predominant cardiac adult isoform and is highly regulated during acute 
cardiac stress.53 GLUT4 is in addition, insulin-responsive34 and highly 
regulated at the pre- and post-translational levels.35, 36, 54 The cardiac 
developmental mRNA expression pattern of GLUT 4 is inverse to that of 
GLUT1, with low expression in the foetal heart and high expression in the 
normal adult heart. 52 
Four hexokinase isoforms have been characterized, and, like the 
glucose transporters, they show differences in tissue distribution. HK I is 
thought to be ubiquitous, but in a similar pattern to GLUT1, is more highly 
expressed in the foetal heart and downregulated at the level of gene 
expression in the adult heart. 52 HK II, is seemingly coordinately regulated 
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with GLUT4 and is higher in the adult than foetal heart and is expressed in 
insulin-sensitive tissue. 52 
PFK contributes to the regulation of intermediary steps of glycolysis 
and three isoenzymes of PFK-1 have been described in rodents.55 The 
muscle isoform (PFK-M) is enriched in cardiac and skeletal muscle and is 
known to be markedly regulated during skeletal muscle differentation, with 
a 5-7 fold induction during myoblast to myotube differentiation of C2 
cells. 56 The cardiac developmental expression patterns of the PFK 
encoding gene isoforms have not yet been described. A second 
phosphofructokinase. PFK-2 is also an important enzyme in glycolytic flux. 
The activity of this enzyme has been shown to increase when glycolytic 
flow is increased in response to insulin or increased heart work. 57 
To advance the understanding of the molecular regulation of the 
genes encoding the adult-enriched glucose transporter (GLUT4) and of 
PFK-M during cardiac development. with the onset of cardiac hypertrophy, 
and following antihypertensive treatment in hypertensive rats the mRNA 
expression patterns of these genes were evaluated in our studies. 
Although these data are a minor aspect of the dissertation. they do 
contribute to the broader concept of the role of gene regulation in cardiac 
metabolism. The new paradigm that genomic regulation plays a role in 
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directing cardiac metabolism is considered further in the discussion 
section of this dissertation. 
Regulation of Fatty Acid Metabolism 
Lipids are a major source of energy in differentiated cardiac muscle and 
are used in preference to glucose in aerobic conditions. However. 
compared to glucose metabolism, the control of lipid metabolism in muscle 
is less well understood. The heart does contain a certain amount of stored 
triacylglycerol. however, the activity of triacylglycerol lipase, which is 
required to mobilize these stores are low. In the rat heart, for example, the 
activity of triacylglycerol lipase is less than one percent of the activity of 
phosphofructokinase. 58 However, this endogenous triglyceride pool may 
account for up to 50% of the myocardial energy requirement in the 
absence of exogenous fatty acids. 59 This would be a very rare event and 
accordingly the main source of lipids for oxidation in the heart is derived 
from the circulation. These are carried in the circulation as either free fatty 
acids bound to albumin, as triacylglycerol or in lipoprotein particles. 
A major factor in the control of lipid oxidation appears to be 
substrate supply. This concept was initially introduced by Randle and 
colleagues in 1963 and was described as the 'glucose fatty-acid cycle'. 60 
In these experiements, Randle demonstrated that the metabolic 
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relationship between glucose and fatty acids were both reciprocal and 
partially dependent (reviewed61 ). An additional convincing mechanism, 
which has been suggested, is at the stage of acetyl CoA. It seems highly 
unlikely, however, that regulation of the supply of circulating lipid and by 
feedback inhibition by the end-product on an enzyme distal in the ~­
oxidation pathway are sufficient control points for exquisite regulation of 
this pivotal cardiac fuel SUbstrate. Data implicates additional regulatory 
control at the level of fatty acid import into the mitochondria via carnitine 
palmitoyaltransferase enzymes. 62-64 The regulation of carnitine 
palmitoyltransferase is exquisite, and is dependent on numerous 
enzymes, kinases and substrates (described in detail in the referenced 
manuscripts65-68). Other mechanisms to coordinate the rate of fatty acid 
oxidation with the energy demand of the contracting myocyte are expected 
to be operational. However, if there are other sites of regulation they have 
yet to be well defined and characterized. The fatty acid ~-oxidation cycle is 
illustrated in Figure 2. 
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Figure 2. The ~.oxidation pathway of fatty acids and specific defects causing 
cardiomyopathy . 
The pathways of fatly aCid oxidation and cellular carnitine metabolism are shown. 
Defects known to cause cardiomyopathy (indicated by the asterisks) Include 
abnormalities in carnittne and acylcarnitine transport, carnit ine palmitoyllranslerase I 
and II (CPT I and II) deficiency, and carnltine-acylcarnitine translocase (translocase) 
deficiency - and errors in steps 1 and 3 of mitochondrial /l-oxidation. long-chain and 
medium-chain acyl coenzyme A dehydrogenase (AD) deficiencies and long-chain 3-
hydroxyacyl-coenzyme A dehydrogenase (LCHAD) deficiency. respectively. LCFA. long 
-chain fatly acids, LCAS. long-chain acyl-CoA synthetase. 
The Foetal Gene Programme and Cardiac Dysfunction 
NumerolJs investigators have demonstrated. while studying the molecular 
regulatory events associated with cardiac hypertrophy. that there is a re-
expression of the foetally enriched isoforms of numerous genes encoding 
cardiac contractile and ion regulatory proteins.69-74 The current 
paradigm, therefore implies that the activation of the "foetal gene" 
programmes induce adaptive structural and metabolic responses of the 
overloaded ventricle to maximize chemomechanical energy conversion 
efficiency, and thereby decrease oxygen consumption in the hypertrophied 
heart. This reversion to the expression of foetal isoforms is paralleled at 
the metabolic level in the switch in energy substrate utilisation in the heart 
during the development of cardiac hypertrophy and failure. In this body of 
work we have begun to explore and characterise the regulation of the 
genes encoding metabolic enzymes required to orchestrate the use of 
specific fuel substrate during cardiac development and with the onset of 
cardiac hypertrophy and the transition to heart failure. 
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The Gene Regulatory Programme 
The study of inherited disorders resulting in cardiomyopathy discussed 
above has given us insight into multiple potential mechanisms in the 
development of cardiac contractile dysfunction. To further enhance the 
understanding of the development of cardiac hypertrophy and the 
transition to heart failure, an approach would be to delineate and 
characterize the gene regulatory programmes activated during the 
development of these pathologies. Using this strategy, one can focus on 
cardiac genets thought to be regulated by relevant pathologic cardiac 
stimuli such as pressure overload. Subsequently, the components of the 
pathway upstream of the candidate gene of interest can be characterized 
in "reverse" from the gene's promoter (on/off switch), to the promoter 
binding transcription factors (gene regulatory proteins), to intracellular 
signalers and finally to the membrane receptor and their ligand/s (Figure 
3). 
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Figure 3. Schematic representation of a gene regulatory programme 
in response to a pathophysiologic stimulus. 
The extracellar stimulus elicits a direct or a ligand/receptor-mediated 
response which couples to appropriate signal-transduction pathways. The 
intracellular signal transduction pathways activate specific transcription 
factors (regulatory proteins) to increase or decrease the transcription of 
target genes. These transcription factors bind to defined regions of the 
candidate gene promoter to modulate gene transcription. Translation of 
these genes result in the production of proteins in response to the initial 
extracellular stimulus. 
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This reverse approach has been used recently to elucidate adaptive and 
maladaptive responses of the cell during hypertrophy and in the failing 
heart (Reviewed 28, 74). We have used this reverse approach strategy in 
this body of work by focussing on a single rate-controlling energy 
substrate pathway enzyme encoding gene (medium chain acyl-CoA 
dehydrogenase [see figure 2]). 
However. we firstly evaluated the expression patterns of numerous 
genes encoding multiple fatty acid and glucose metabolic enzymes during 
cardiac development and with the onset of cardiac hypertrophy (Illustrated 
in figures 1 and 2). As will be described, we demonstrated a coordinate 
expression pattern of genes encoding multiple metabolic enzymes during 
cardiac development and with the onset of cardiac hypertrophy. Thereafter 
using this 'reverse' strategy to understand gene regulation we focussed on 
evaluating the gene regulatory programme directing medium chain acyl-
CoA dehydrogenase in cardiac development, with the onset of cardiac 
hypertrophy and during established heart failure. 
In the preliminary studies we established that medium chain acyl-
CoA dehydrogenase was highly regulated at the gene expression level 
during cardiac development and with the onset of cardiac hypertrophy. 
Further characterization of medium chain acyl-CoA dehydrogenase was 
therefore directed at evaluating the regulation of this gene at the 
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transcriptional level. Transcriptional regulation is, in part, dependent on 
the regulatory elements contained within the gene's promoter region. 
This structural region (promoter) directs the expression of a gene in 
response to physiologic or pathologiC signals (see Figure 3). Thus we can 
construct modified genes which include the candidate gene's promoter 
region fused to a reporter gene (see schematic diagram in Figure 4). By 
measuring the activity of this reporter gene in-vitro we can begin to 
understand which transcriptional factors modulate the regulation of this 
gene in response to different stimuli. Moreover, this transgenic construct, 
can be randomly inserted into the mouse genome. Subsequent 
measurement of the activity of the reporter gene allows us to determine 
the ability of the incorporated promoter region to tum on (upregulate) or off 
(downregulate) the reporter in response to physiologic and pathologiC 
stimuli in-vivo. Subsequent promoter region DNA:protein binding studies 
may identify the transcription factors that bind to the promoter and direct 
the appropriate regulation of the candidate gene. All of these types of 
studies were performed by myself to evaluate and characterize the 
regulation of medium chain acyl-COA dehydrogenase during cardiac 
development and with the development of cardiac hypertrophy and are 
described in detail during the remainder of the text. Of note multiple 
studies to characterize the regulation of medium chain acyl-CoA both in-
vitro and in-vivo have previously been performed in Dr. Kelly's 
50 
laboratory75-BO prior to my work and these studies were the essential 
foundation to enable me to advance this area of study. 
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Figure 4. Schematic representation of a transgene generated which 
Incorporates the human medium chain acyl-CoA dehydrogenase 
promoter and a reporter gene. 
The human MCAD promoter region from - 371 base pairs (bp) upstream of 
the transcription start site (TSS) to + 189 bp downstream of the TSS is 
shown fused to an exogenous reporter gene. The reporter gene activity is 
a measure of the activity of the human MCAD promoter in-vivo. The 
nuclear receptor response element 1 (NRRE-1) and the GC nucleotide 
rich sequence (Site A) are two distinct regulatory regions of the promoter. 
The functional significance of these regulatory elements are discussed in 
the text. The nuclear regulatory transcription factors, Coup-TF, Sp1 and 
Sp3 are described in greater detail in the results section of the text. 
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Manipulation of Candidate Genes to Evaluate Their Functional Role 
in the Development of Cardiac Hypertrophy and Heart Failure 
An alternate molecular approach to evaluate the functional role of 
metabolic genes in the development of cardiac hypertrophy and heart 
failure is the use of genetic manipulation of candidate genes in mice with a 
careful evaluation of the cardiac phenotype. Of note, we did not undertake 
any genetic ablation or gene overexpression studies for this body of work. 
However, to illustrate how this approach can also be used to evaluate the 
role of metabolic genes in the development of cardiac hypertrophy I have 
briefly described the studies of the genetic ablation of the cardiac enriched 
glucose transporter encoding gene - GLUT4 in the following section. 
Genetic Manipulation of GLUT4 Transporter Encoding Gene 
With the development of cardiac hypertrophy, aerobic glycolysis from 
exogenous glucose is accelerated.81 , 82 The uptake of exogenous 
glucose is regulated by the transmembrane gradient and by the 
concentration and activity of the facilitative glucose transporters. The 
GLUT4 isoform of the glucose transporter family, is insulin-sensitive and 
highly expressed in the adult heart, skeletal muscle and adipose tissue.83 
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The process of insulin-stimulated glucose uptake is defective in the 
muscle of patients with type II diabetes84. Thus there is considerable 
interest in the mechanism of GLUT 4 activation and the establishment of 
methods by which this 'insulin-resistance' can be overcome. The ablation 
of the GLUT 4 gene was undertaken by homologous recombination 
[(GLUT4-/_)11J. Using these mice investigators were able to determine the 
developmental and metabolic consequences of abolishing the most 
abundant glucose transporter in insulin target tissues including the heart. 
The mice deficient in GLUT4 are growth-retarded, experience 
decreased longevity, develop cardiac hypertrophy and exhibit severely 
reduced adipose tissue deposits. In addition, these mice exhibit 
postprandial hyperinsulinaemia, indicating possible insulin resistance and 
increased expression of cardiac GLUT1. The authors conclude that 
. functional GLUT 4 protein is essential for sustained growth, normal cellular 
glucose and fat metabolism, and expected longevity.11 The significant 
cardiac hypertrophy in these GLUT4 null mice is thought to be due to the 
hyperinsulinaemia (functioning as a growth factor) in these animals, and/or 
the due to the decreased supply of free fatty acids to the heart. 
Importantly, insulin-resistance has been described in hypertensive and 
failing heart conditions.85, 86 Likewise, reduced free fatty acid utilization 
by the heart as exhibited via pharmacologic inhibition of fatty acid ~-
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oxidation31 , 87, 88 and in the genetic defects in fatty acid utilization29 is 
known to induce cardiac hypertrophy. The mechanisms of these 
phenomena are, however, unknown. Further characterization of the 
GLUT 4 deficient mice has suggested that another probable hypertrophic 
inducing factor is the development of hypertension as shown in the 
heterozygous knockout GLUT4 mice (GLUT4+1-).89 
Interestingly, as with the fatty acid utilizing enzyme genes, GLUT4 
is highly regulated during development, with low expression in the foetal 
and neonatal stages, and high expression in the adult myocardium. 52 We 
and others have demonstrated that at the level of gene expression and 
whole cell protein levels, GLUT 4 reverts to foetal levels with the 
development of pressure overload-induced cardiac hypertrophy.90 This 
seems counterintuitive, as GLUT4 is the predominant cardiac glucose 
transporter, and glucose utilisation is known to be increased in cardiac 
hypertrophy. The metabolic substrate utilization studies in the GLUT4 
ablation studies described above, however, demonstrate that despite a 
complete absence of GLUT4, glucose uptake and utilization are increased 
in the hypertrophic GLUT4 deficient mice compared to normal controls.91 
In these studies. the level of GLUT1 is augmented and probably 
overcompensates for the loss of GLUT4.11 
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Thus, although not conclusive these studies into the GLUT4 
knockout mice do illustrate an alternative and complementary approach to 
delineate the genomic role of energy substrate use in the development of 
cardiac hypertrophy. The manipulation of other cardiac enriched metabolic 
enzyme encoding genes, including that of a fatty acid metabolism92 are 
ongoing and should expand our understanding of the role of substrate use 
in the development of cardiac hypertrophy. Moreover, the manipulation of 
the transcriptional pathways directing these fatty acid enzyme encoding 
genes93, 94 are ongoing and should give us further insight into the role of 
the regulation of metabolic enzymes and the development of cardiac 
hypertrophy and heart failure. These studies are however beyond the 
scope of this dissertation and are, in part, an extension of this work.93, 94 
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Project Aims 
The objectives of this body of work were to: 
i) Determine the expression patterns of genes encoding key rate-
controlling enzymes in the major cardiac energy catabolic 
pathways, including fatty acid p-oxidation and glycolysis during the 
cardiac development and with the onset of cardiac hypertrophy. 
ii) Delineate and characterize the molecular programme directing a 
target metabolic gene (medium chain acyl-CoA dehydrogenase) 
during cardiac development, with the onset of pressure-overload 
induced cardiac hypertrophy and with the progression to 
decompensated heart failure. 
The futlJre objectives of this work include the genetiC manipulation of the 
regulatory mechanisms identified, to begin to understand the role of 
altered fuel substrates in the development of cardiac hypertrophy and 
heart failure. 
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Materials and Methods 
Cardiac Tissue Samples 
In order to evaluate metabolic gene regulation during cardiac 
development, rats were sacrificed at various time points of development 
during the foetal and postnatal periods. To evaluate the regulation of the 
metabolic genes with development of cardiac hypertrophy a mouse model 
of right ventricular hypertrophy was used. Thereafter, to evaluate the 
transcriptional regulation of a candidate gene in-vivo, we utilized the same 
mouse model of cardiac hypertrophy, however, in this instance the 
experiments were performed in transgenic mouse harbouring our gene 
promoter of interest. Subsequently, neonatal rat hearts were extracted to 
prepare primary cardiac cell cultures for gene promoter transfection 
studies. To study the temporal regulation of these metabolic genes with 
the development of cardiac hypertrophy and heart failure, numerous 
genetiC rat strains of pressure overload were studied (described below). In 
an attempt to extrapolate these data to the human heart, we did evaluate 
the regulation of some of these metabolic genes in explanted hearts from 
recipients of heart transplants and from age-matched controls. These 
various heart preparations are described in greater detail below. 
59 
Cardiac Developmental Time Points 
To evaluate the mRNA expression patterns of genes encoding 
representative metabolic enzymes during cardiac development, we 
extracted heart tissue from Wistar Furth Rats at various time points during 
cardiogenesis. The rat foetus develops over 21 days, and an established, 
contracting four chambered heart is evident after 9.5 - 10.5 days of 
embryologic development (e9.5 - e10.5)95. Embryonic heart tissue was 
studied at days 16-19 (e16 - e19). and postnatally (p) at days p1, p7. p14, 
p21 and p70. The rats were sacrificed in a CO2 chamber. and the hearts 
excised and stored at -SOoC, for subsequent extraction of RNA and 
protein. 
MOdels of Cardiac Hypertrophy· Heart Failure 
The Pulmonary Artery Banded Mouse Model 
Current molecular genetics technology allows researchers to genetically 
manipulate the mouse genome. facilitating the subsequent functional 
characterization of the role of proteins of interest in physiology and 
pathophysiology in-vivo. To exploit this technology in the assessment of 
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fatty acid metabolic gene regulation in the heart, we initially characterized 
the regulation of fatty acid oxidation enzyme encoding genes in mice 
(C57SU6 x SJUJ mice) with induced right or left ventricular hypertrophy. 
The right and left ventricular hypertrophy was induced via Pulmonary 
artery banding (PAS) or thoracic aortic arch banding (TAC) surgery 
respectively, in the laboratory of Howard Rockman, MD (University of 
California, San Diego).96, 97 The PAS was performed as follows: mice 
underwent induction of anesthesia and intubation, the main pulmonary 
artery was isolated by blunt dissection and a suture was placed around 
the vessel and tied against a 25-gauge blunt needles to produce a 
stenosis. Sham-operated animals (n = 24) underwent the identical 
surgical procedure except that the constriction was not placed. After 7 
days, animals from the PAS and sham groups were sacrificed and 
ventricular and atrial chambers were dissected out and snap frozen. 
Seven days was deemed to be a reasonable time point to assess 
hypertrophic indices, as the hearts had hypertrophied to a significant 
degree by this time point. 96, 97 The mean age of the mice was 9 months 
with a similar distribution of male and female animals between the PAS 
and control groups. The T AC procedure was performed in a similar 
way.97 The differences included a smaller blunt needle for the constriction 
size (26- gauge) and the experiments lasted 14 instead of 7 days. The 
heart tissue was stored at -70°C for subsequent RNA, DNA and Protein 
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analysis work. FAO enzyme gene expression patterns were compared in 
the PAS and sham operated littermate control mice and between the TAC 
operated mice and their respective controls. 
The right ventricular hypertrophy induced by pulmonary artery 
banding was more significant, with a greater degree of regulation of FAO 
enzyme gene expression (discussed in results). We thus used the PAS 
approach to evaluate the role of gene transcription of medium chain acyl-
CoA dehydrogenase gene expression with the development of cardiac 
hypertrophy. Prior to my arrival in Dan Kelly's laboratory, extensive studies 
had been performed to clone, sequence and characterize the human 
medium chain acyl-CoA dehydrogenase gene promoter. The human 
medium chain acyl-CoA dehydrogenase promoter had being 
characterized by: footprinting experiments: transfection into transformed 
cell lines and via the generation of transgenic mouse lines with the 
incorporation of different length promoter constructs downstream of the 
chloramphenicol acetyltransferase gene into their genome.76-79 The 
promoter elements required for appropriate tissue and developmental 
regulation of the medium chain acyl-CoA dehydrogenase gene 
expression, under normal physiologic conditions, had thus been identified. 
The promoter region inclusive of all these elements lay within 371 base 
pairs of the transcription start site. The transgenic mice lines harbouring 
this construct were called MCADCAT.371. A deletion construct with 
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removal of the most distal regulatory element was called MCADCAT.317. 
The regulatory elements present in this 371 base pair promoter region are 
illustrated in Figures 4 and 5. The pulmonary artery banding procedure 
and parallel sham control operations were performed in genetically 
modified mice with the incorporation of the human medium chain acyl-CoA 
dehydrogenase gene promoter/reporter construct into their genome. The 
promoter region is described in further detail in Figures 4 and 5. 
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Figure 5. Schematic representation of the full-length human medium 
chain acyl-CoA dehydrogenase promoter reporter construct used for 
subsequent analysis of the transcriptional regulation of medium 
chain acyl-CoA dehydrogenase in response to pressure-overload. 
The full-length human medium chain acyl-CoA dehydrogenase promoter-
CAT reporter construct - MCADCAT.371 is shown schematically. 
MCADCAT.371 includes a human medium chain acyl-CoA 
dehydrogenase gene promoter fragment (horizontal line) containing 371 
bp upstream to 189 bp downstream of the transcription start site (arrow) 
fused to a bacterial CAT gene-simian virus 40 (SV40) 
intron-polyadenylation signal sequence. The positions of the three known 
transcriptional regulatory units in the medium chain acyl-CoA 
dehydrogenase gene promoter are represented. Each unit is composed 
of a nuclear receptor element (NRRE-1, N2 or N3) and a GC-rich box (A, 
B, or C). The sequence of potential nuclear receptor binding sites 
(arrows) within NRRE-1 is also shown. The deletion construct with 
removal of the most distal regulatory element is called MCADCAT.317 and 
is schematized in Figure 9. 
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The Spontaneously Hypertensive/Heart Failure Rat Model 
The SHHF/MccfaCP rat developed by S.A. McCune (The Ohio State 
University), is a genetically inbred strain that develops hypertension, LV 
hypertrophy and congestive heart failure.98, 99 This strain originated from 
a cross of the Koletsky rat and the spontaneously hypertensive rat (SHR) 
from the NIH colony. Offspring are lean (75%) or obese (25%). All lean 
male SHHF animals develop hypertension and left ventricular hypertrophy 
(LVH) by 3-5 months of age and eventually develop overt congestive HF 
by 16-20 months of age. Only lean, normoglycemic, male SHHF rats were 
used for this study at different stages in the natural progression to heart 
failure. Two month old SHHF males that had not yet developed 
hypertension were used as control rats (C, n = 6). A second group of 9-12 
month old animals with established hypertension and concentric LVH 
without dilatation served as the compensated LVH group (n = 5). The 
third group consisted of animals at 16-20 months of age with overt 
congestive HF (n = 6). Previous characterization of the SHHF male lean 
rats with Doppler and M-mode echocardiographic studies of lean male 
SHHF rats98 have demonstrated that between 13 and 17 months of age, 
shortening fraction decreases, LV diastolic and end-systolic diameters 
increase, and aortic velocity time integral x heart rate decrease 
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significantly in male lean SHHF rats compared to animals in the LVH 
group (ages 9-12 months). All older SHHF rats used for this study 
exhibited the external clinical signs of heart failure, including: dyspnoea, 
cyanosis, piloerection, lethargy and cold tails; and, internally they had 
ascites, pulmonary edema, and pleural effusion. The heart failure hearts 
were enlarged with thickened left and right ventricular walls, dilated 
lumina, left and right atrial dilatation and frequently contained left atrial 
thrombi. At the ages indicated, the rats were weighed, anesthetized with 
pentobarbital, and sacrificed. The whole heart was removed, weighed and 
ventricles dissected out, snap frozen. To control for the effect of age on 
gene expression, LV tissue was obtained from a related rat strain [Wistar-
Furth (WF)] at 2 and 17 months. The WF rats do not develop 
hypertension, L VH or HF. 
The Spontaneously Hypertensive Rat Model and the Attenuation of 
LVH Development in the SHR's USing Carvedilol 
To further evaluate the rnRNA expression pattern of metabolic genes with 
the onset of pressure overload induced-cardiac hypertrophy9 we studied 
metabolic gene expression patterns in left ventricular tissue extracted from 
adult (24 week) SHR rats (Harlan, UK) (n=10) compared to age matched 
WF controls (n=10). Previous characterization of the SHR rats have 
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demonstrated hypertension in 100% of the rats by the age of 10 weeks 
and increased LV weight to body weight ratios are characteristic after 13 
weeks of age.1 00 At 24 weeks the rats were weighed, anesthetized with 
pentobarbital, and euthanized. The whole heart was removed, weighed 
and ventricles dissected out, weighed and snap frozen. To control for the 
effect of age on gene expression, LV tissue was obtained from the related 
age-matched normotensive Wi star Furth rat strain. 
To evaluate the effect of attenuation of hypertrophic growth on 
metabolic enzyme gene expression in the SHR's, a groups of these rats 
were fed a diet supplemented by carvedilol [(at 2400 ppm) (n=9)] or 
placebo supplemented diet (n=7) for four weeks from the age of 20 weeks. 
This experimental protocol has previously been administered to SHR's, 
and has demonstrated a reduction in blood pressure and a concomitant 
attenuation in the advancement of LVH.101 In addition, a group of WF 
rats were also fed a diet sLipplemented by carvedilol over the same 4 
week period (n=5). The rats were again sacrificed at 24 weeks of age, and 
the LV tissue handled as described before for subsequent RNA extraction. 
Human Heart Failure 
The heart failure group was comprised of 8 heart transplant recipients 
enrolled in the Heart Transplantation Programme at Barnes Hospital, St 
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Louis, Missouri, USA. Inclusion criteria for the heart failure samples 
included patients who experienced heart failure symptoms with minimal to 
no exertion (New York Heart Association Functional Class III to IV) and an 
ejection fraction < 35% as determined by radionuclide ventricular 
angiography and confirmed by left ventriculography at the time of cardiac 
catheterization. Subjects were excluded if heart failure was the result of 
an acute insult (e.g. cardiogenic shock from an acute myocardial 
infarction), if the subject had an implanted left ventricular assist device, or 
if the patient remained on bypass for more than 30 minutes prior to 
explantation of the heart. The control group included 5 postmortem 
samples from hearts of individuals who had died from non-cardiac causes. 
The control hearts were rejected as transplant donor organs due to 
positive cytomegalovims serology in 2 subjects, age of patient in one, and 
for unknown reasons in the final two controls (gross cardiac pathology was 
excluded by palpation of the coronary arteries, viewing cardiac wall 
thickness and a normal heart weight to body weight ratio at the time of 
harvest). Left ventricular apical tissue obtained immediately after the heart 
was removed from the subject's chest was snap frozen in liquid N2 and 
stored at -BOoC until total RNA and protein were isolated. 
69 
RNA Analysis 
RNA Extraction and Quantitation 
Total RNA was extracted from 25-100 mg of frozen heart tissue. All 
samples were kept on ice during extraction to prevent RNA degradation. 
The tissue was completely homogenized in 2 ml of RNAzol B (Biogenesis, 
Poole, UK) to prevent enzymatic degradation of the RNA. Fatty acids and 
proteins were removed by extraction with chloroform as follows: The 
homogenate was vortexed for 15 seconds with 200 J.LI of chloroform and 
left to incubate, on ice, for five minutes. The aqueous and organic layers 
were separated by centrifugation (11,500 g for 15 minutes at 4°C) and the 
top aqueous layer removed to a fresh sterile tube. The chloroform 
extraction was repeated, using 1 ml of chloroform, and the top aqueous 
layer again removed to a fresh sterile RNAse free tube. One ml 
isopropanol was added, the samples vortexed and then stored overnight 
at -20°C to precipitate the RNA. The following day, samples were 
centrifuged at 11,500 g for 15 minutes at 4°C, to pellet the RNA, and the 
supernatant was decanted. The pellet was re-suspended in 1 ml 75% v/v 
ethanol, to wash away salts precipitated by the isopropanolol and then 
reformed by centrifugation (11,500 g for 10 minutes at 4°C). The ethanol 
was decanted, the last few drops carefully removed using a pipette, and 
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the pellet allowed to air-dry for 30 seconds. The RNA was re-suspended in 
20 ,..,1 0.1 % v/v DE PC-treated water and stored at -BOoC. 
Two ,..,1 of the prepared RNA was diluted 1 :500 in sterile distilled 
water and the absorbance at 260 nm (A26onm) measured using a 
spectrophotometer. The total RNA concentration ([RNA]) was determined 
using the following equation: 
Total [RNA] (,..,g1ml) = A260nm X dilution factor (500) x 40 ,..,g/ml 
The values obtained were divided by 1000 to arrive at a concentration in 
units of ,..,g/,..,1. The absorbance of the diluted RNA was subsequently 
measured at 280nm (A280nm). The ratio of A260nm:A280nm was calculated to 
determine the protein contamination within the RNA samples. Pure mRNA 
will have a A260nm:A28Onm ratio of 2. Using total RNA, the RNA was 
considered of sufficient quality for Northem blot analysis if the ratio were> 
1.7. 
RNA Gel Electrophoresis and Capillary Transfer to Nylon Membranes 
A denaturing 1.2% agarose gel for RNA separation was prepared as 
follows. Agarose (2.4g) was dissolved, by heating (100°C), in 146 ml of 
sterile distilled water. A pre-warmed solution (60°C) of 37% v/v 
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formaldehyde (16.2 mls) and 20 mls of 10x MOPS, were added to the 
warmed agarose and poured into a gel casting apparatus (BIORAD, USA). 
The total RNA samples were prepared for gel electrophoresis as 
follows: A 20 Jlg sample of total RNA was diluted in 0.1 % DEPC water to a 
volume of 6 Jll. The RNA samples were suspended in 19.3 JlI of buffer 
containing; 12.5 JlI of de-ionized formamide; 4 JlI of 37% v/v formaldehyde; 
2.5 JlI of 10x MOPS solution and 0.3 JlI of 0.5 mg/ml ethidium bromide. 
Samples were incubated at 60°C for 15 minutes and then placed on ice for 
two minutes. 2.5 JlI of loading dye was added to each sample, which were 
then mixed and quickly spun in a micro-centrifuge to bring the sample to 
the bottom of the tube. A previously poured and set gel was immersed in 
1x MOPS and the samples carefully loaded into the gel wells. Total RNA 
was separated electrophoretically at 80 V for four hours. The equivalence 
of RNA loading was visually confirmed by ultra-violet light, as the intensity 
of the orange fluorescence produced by the binding of ethidium bromide to 
RNA is proportional to the RNA concentration. In addition, the integrity of 
the RNA was confirmed by visualizing the ratio of the 28s to 18s bands 
(>2) and by the lack of additional smaller degradation banding I smearing. 
The electrophoretically separated RNA was transferred onto a 
nylon membrane (Hybond-N; Amersham Life Sciences, USA and UK). via 
capillary transfer. 
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Northern Blot Analysis 
The cDNA fragments described below were used for Northern blot 
analysis. The cDNA fragments were radiolabelled with a-p32-dCTP, using 
the Boerhinger Mannheim, random primer labelling kit and the Klenow 
enzyme. Two ~I of the final labeled probe was used for Cherenkov 
counting on a Beckman Scintillation counter. The final volume of probe 
used for labelling was calculated to include a final count of 3 -5 x 106 cpm 
in the hybridization solution. Stratagene quickhyb solution was used for 
the prehybridization and hybridization steps. To reduce non-specific 
background hybridization of the radiolabelled cDNA probe, adjuvant pre-
boiled sonicated salmon sperm cDNA was added to the hybridization 
solution. 
cDNA Probes used for Northern Blot Analysis: 
LeAS The rat gene encoding long-chain acyl-CoA synthetase. This 
cytosolic enzyme catalyzes the formation of fatty acyl-
coenzyme A thioesters from free fatty acids in the cytosol. 
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M-CPT I 
MCAD 
the muscle isoform of camitine pa/mitoyltransferase I, the 
integral outer mitochondrial membrane protein that catalyzes 
the initial step in mitochondrial import of long-chain 
acyl-CoA. 
The rat gene encoding medium chain acyl Co-A 
dehydrogenase, a nuclear encoded enzyme that catalyzes 
the first step of medium chain fatty acid catabolism in the 
mitochondriall3-oxidation cycle. 
LCAD The rat gene encoding long chain acyl CoA dehydrogenase. 
LCHAD 
GLUT4 
PFK-M 
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a nuclear encoded enzyme that catalyzes the first step of 
long chain fatty acid catabolism in the mitochondrial 13-
oxidation cycle. 
the C-terminal portion of the human ex. subunit of 
mitochondrial trifunctional protein which catalyzes the third 
step of long chain fatty acid catabolism in the mitochondrial 
l3-oxidation cycle. 
The rat gene encoding the cardiac adult-enriched glucose 
transporter. 
The rat gene encoding the muscle isozyme of 
phosphofructokinase. This enzyme phosphorylates D-
fructose 6-phosphate to D-fructose 1,6-diphosphate. 
committing the glucose byproduct to the glycolytic pathway 
GAPDH The human gene encoding the ubiquitous glycolytic enzyme 
gene, glyceraldehyde-3-phosphate dehydrogenase. 1 02 This 
enzyme catabolizes the first step in glycolysis which 
generates ATP production. Interestingly, due to the relative 
abundance of this enzyme GAPDH is often considered as a 
"housekeeping gene", and used by investigators to evaluate 
loading on RNA electrophoretic gels. 
ATPe A partial cDNA coding and 3' untranslated region sequence 
(164 bp) of a nuclear-encoded mitochondrial protein. mouse 
ATP synthase subunit e was obtained by reverse-
transcription polymerase chain reaction amplification. 1 03 
ANF The rat gene encoding atrial natriuretic factor (AN F). This 
gene is predominantly expressed in the fetal heart and the 
adult atria. Re-expression in the ventricles are known to 
occur. following pressure -overload. 
cTNI The rat gene encoding the contractile protein - cardiac 
troponin I. This protein is considered not to be regulated at 
the gene expression level in the adult cardiac ventricle. 
Il-actin The rat gene encoding a myocyte cytoskeletal protein. used 
to control for standardising RNA loading 
18s Ribosomal cDNA probe to control for minor differences in 
RNA loading or RNA integrity. 
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Total RNA isolation and Northern blot analyses were performed as 
described above 104 using the cDNA probes discussed above. Mouse 
ATP synthase subunit e103 was obtained by reverse-transcription 
polymerase chain reaction amplification. The signals were quantified by 
laser densitometric analysis within the linear range of film sensitivity. The 
densitometric values shown were normalized to the signal obtained with 
an 18s ribosomal cONA probe to control for minor differences in RNA 
loading or RNA integrity. 
Total Protein Extraction 
Total cellular protein was prepared from the human and rat left ventricle 
for immunoblot analysis. In brief, 25 to 50 mg of fresh tissue was 
sonicated in lysis buffer solution (10 mM Tris, 5 mM EGTA, 0.1 mM on 
at pH 7.2). The following protease inhibitors including 2mM PMSF and 
0.125 Ilg/ml Leupeptin and SOS to a final concentration of 0.5% were 
added fresh to the lysis buffer prior to use. Once sonicated and in 
solution, the samples were spun at 5 000 rpm for 5 minutes. The 
supematant was placed in a 'fresh eppendorf tube and quantitated using 
the Lowry assay for subsequent use for Western Blot analysis. 
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A modification of the protein immunoblot (Western) analysis 
described previously 104 was performed using the Enhanced 
Chemiluminescence detection system (Amersham). Primary antibodies 
used include: a polyclonal rabbit antibody to porcine medium chain acyl-
CoA dehydrogenase75 and a polyclonal antibody to the C-terminal actin 
fragment [universal actin antibody (Sigma Immunochemicals, St. Louis, 
MO.)]. A horseradish peroxidase-conjugated secondary antibody to rabbit 
IgG was used on all blots. 
Nuclear Protein Extraction 
The nuclear protein extraction technique was specifically adapted for the 
preparation of DNA-binding proteins from animal solid tissues. 1 05 In brief, 
between 100 and 500 mg of heart tissue was ground to powder using a 
mortar and pestle under liquid N2. All subsequent steps were performed in 
a walk in +4°C laboratory. The thawed powder was homogenized using a 
glass dounce homogenizer in 5 mls of solution A (0.6% Nonidet P-40, 150 
mM NaCI. 10 mM HEPES pH 7.9, 1 mM EDTA, 0.5 mM PMSF). This 
solution was then incubated on ice for 5 minutes and then centrifuged for 
5 minutes at 5000rpm. The pelleted nuclei were then resuspended in 100-
500 J-li of solution B (25% glycerol, 20 mM HEPES pH 7.9,420 mM NaCl, 
1.2 mM MgCI2, 0.2 mM EDTA, 0.5 mM dithiothreitol [DTT], 0.5 mM PMSF, 
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2 mM benzamidine, 5 jlg/mL of each of the three protease inhibitors: 
pepstatin, leupeptin and aprotinin) and then incubated on ice for 20 
minutes for high salt extraction. The lysed nuclei were transferred to a 
microcentrifuge tube and cellular debris pelleted by a 15 second 
centrifugation. The supematant containing the DNA-binding proteins was 
then aliquoted into small fractions, frozen in liquid N2 and stored for 
subsequent use at -80°C. 
Protein Quantitation 
To ensure accurate reproducible measurements of protein content in the 
various heart tissues, a modified Lowry method was adopted as described 
by Peterson et al.1 06 Using distilled deionised water, the protein samples, 
blanks and bovine serum albumin standards (between 5 and 100 jlg's) 
were brought up to a volume of 1.0 ml. One ml of reagent A (see 
appendix) was added to each sample, the sample was vortexed and 
allowed to stand for 10 minutes to allow complete dissolution of the 
precipitate. An additional 0.5 ml of the reagent B (see appendix) was 
added. The reaction was vortexed immediately as the t112 of the 
phosphomolybdate regent is only 8 seconds. The tubes were then allowed 
to stand at room temperature for 30 minutes. Absorbance was then 
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measured spectrophotometrically using visible light at a A. of 750nm. A 
standard curve was established using the known bovine serum albumin 
samples. Thereafter, using linear regression analysis and the known slope 
of the standard curve (m), the log values of the proteins samples could be 
calculated from the log A750 intercept of the standard curve (b) using the 
following formula: 
Log (J.1g protein) = m x log(A750) + b 
or 
J.1g protein = 1 O(m x log(A7SO) + b) 
Western Blot Analysis 
Western blot analysis was performed following standard polyacrylamide 
gel electophoresis (10 -15%), electrophoretic transfer to a nitrocellulose 
membrane (Overnight at 25 rnA) and immunoblotting using the Enhanced 
Chemiluminescence detection system (Amersham). Reducing buffers, 
running buffers and transfer buffers are described in the appendix. 
The primary antibodies used include: 
1. Polyclonal antibody to porCine medium chain acyl-CoA 
dehydrogenase.75 
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2. Polyclonal antibody to the C-terminal actin fragment [universal actin 
antibody (Sigma Immunochemicals, St. Louis, MO, USA)]. 
3. Polyclonal antibody to long-chain acyl-CoA dehydrogenase (LCAD; a 
gift from Dr. Arnold Strauss) 
4. Polyclonal antibody to the Sp1 transcription factor (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) 
5. Polyclonal antibody to the Sp3 transcription factor (Santa Cruz 
Biotechnology, Santa Cruz, CAl 
6. Anti-COUP-TF [a gift from A.J. Butler], The anti-COUP-TF antibody 
recognizes both COUP-TFI and COUP-TFII isoforms.107 
7. Anti-peroxisome proliferator activated receptor a [PPARa; a gift from 
Dr. Michael Arand].1 08 
The species specific horseradish peroxidase-conjugated IgG antibodies 
were used as secondary antibodies at a dilution of 1 :3000 in all Western 
immunoblot experiments. 
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Transgenic Mouse Studies 
Production and characterization of the MCADCAT.371 transgenic mice 
has been described.80 These mice have previously been found to have 
appropriate developmental stage specific expression of the medium chain 
acyl-CoA dehydrogenase gene.80 Furthermore, mutant medium chain 
acyl-CoA dehydrogenase promoter transgenic mice lines were also 
studied. These mice have a deletion of the NRRE-1 medium chain acyl-
CoA dehydrogenase promoter region and the promoter construct is 
described as MCADCAT.317. Although the mutant promoter is active, the 
reporter gene does not have the appropriate developmental stage-specific 
expression in the heart.80 Pulmonary artery banding and sham 
procedures were performed on mice from two independent full-length 
transgenic lines and in two MCADCAT.317 mice lines. CAT enzyme 
activities were determined on tissue extracts by use of an assay described 
below. 
Choloramphenicol Acetyl-Transferase Assays 
Protein extracts for CAT assays were prepared by sonication of frozen 
tissue in 0.25M Tris buffer. The suspension was cleared by centrifugation 
and total protein content was determined on the supernatant by the Lowry 
method. CAT assays were performed on 100 mg of total protein, as 
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described previously, with n-butyryl CoA and 14C chloramphenicol 
substrates. Butyrylated chloramphenicol was separated from free 
chloramphenicol by xylene extraction. Samples were counted in duplicate 
on a Beckman LS 6000lC scintillation counter. 
Electrophoretic Mobility Shift Assays 
EMSAs were performed with crude nuclear extracts prepared from pooled 
embryonic (day 16.5 and 19.5) mouse hearts and adult control and 
hypertrophied RVs, as described. 1 09 The following sense strand 
nucleotide sequences represent the probes used in the EMSAs: 371/255 
(the combined NRRE-1/site A sequence) 5'-
ttgaatccgccaagcagacacgatctgggtttgacctttctctccgggtaaaggtgaaggctgaccacg 
ggggccgctctccctccaggccccagccacgccctctaacccaggttc-3'; NRRE-1, 5'-
gatccgggtttgacctttctctccggg-3' and site A, 5'-gatccggccccagcc 
acgccctctaacccag-3'. Antibody "supershift" experiments were performed 
with the antibodies described above except that a different anti-COUP-TF 
antibody was used (a gift from Dr. Ming-Jer Tsai, Baylor University). 
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Primary Cardiocyte Extraction and Cell Culture Gene Reporter 
Transfection Studies. 
Cardiomyocytes were prepared from 1-day-old rats as described,80 
Transient transfections were performed with DOTAP (N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate) (Boehringer 
Mannheim) in 12-well collagen-coated dishes. For each transfection, four 
j.J.g of reporter DNA and two j.J.g of a plasmid containing a ~-galactosidase 
gene downstream of the Rous sarcoma virus promoter (RSV-~gal) were 
added to fifteen j.J.1 of DOTAP-HEPES solution and incubated for 15 min at 
room temperature. In some dishes one j.J.g of pCDM.COUP, a mammalian 
expression vector containing a human COUP-TF I cDNA downstream of a 
CMV promoter77 was added. One j.J.g of pCDM(-), the expression 
plasmid backbone lacking the COUP-TF I cDNA, was added to dishes not 
containing pCDM.COUP. The mixture was subsequently added to the 
primary cardiocytes prior to initial plating. The cells were washed and 
refed the following morning. The cells were harvested 48 h after plating. 
Luciferase activity was measured by the standard luciferin-ATP assay, 
and ~-galactosidase activity was measured by the Galacto-Light 
chemiluminescence assay (Tropix) in an Analytical Luminescence 
Monolight 2010 luminometer. The reporter plasmid used for the 
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experiments (MCADLuc.371) contains the identical medium chain acyl-
CoA dehydrogenase promoter fragment present in the MCADCAT.371 
construct fused to a luciferase reporter in the pGL2-basic plasmid 
(Promega). 
Enzyme Activity Studies 
Medium chain acyl-CoA dehydrogenase activity was determined by 
following the decrease in ferricenium ion absorbance at 300 nM. as 
described.104 Activity is shown as ~mol octanoyl-CoA oxidized per 
minute per gram wet weight. 
Southern Blot Analysis 
Genomic DNA was isolated from human left ventricle using a standard 
protocol.110 The mitochondrial DNA probe was obtained by PCR 
amplification of a region of the human mitochondrial genome (nucleotides 
3108 to 3717) using the following primers: sense-5'-
TTCAAA TTCCTCCCTGTACG-3' and antisense-5'-GGCT ACTGCTCGCA 
GTG-3'. A full-length human GAPDH cDNA probe was also employed in 
these studies to control for loading and for standardization to a nuclear 
gene signal. Fifteen ~g of total genomic DNA. digested with 8amHI 
restriction enzyme at 37°C overnight was loaded to each lane. A standard 
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Southern blotting protocol was used. The final washing solution 
concentration was 0.1 x SSC/1 % SDS for the mitochondrial DNA probe 
and 1 x SSC/1 % SDS for the GAPDH probe at a temperature of 65°C. 
Ethical Approval 
Animal experiments were conducted in strict accordance with the US 
National Institutes of Health (NIH) and UK Home Office guidelines 
regarding humane treatment for the care and use of laboratory animals. 
All animal experiments were reviewed and approved by the Animal Care 
Committees of Washington University, The University of California at San 
Diego, The Ohio State University and University College London, UK. 
Statistical Analysis 
Differences between values for mRNA, protein levels, and enzyme activity 
were determined using unpaired Student t-test analyses (mouse and 
human studies) and one-way analysis of variance (ANOVA) for the rat 
studies. A statistically significant difference was defined as a p value < 
0.05. All values shown represent the mean ± standard error of the mean 
(SE). 
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Results 
Coordinate cardiac developmental mRNA expression patterns of 
rate-controlling fatty acid and glucose utilization enzyme encoding 
genes 
To evaluate whether the expression of genes encoding representative 
fatty acid and glucose catabolic enzymes, parallel the known increase in 
fuel substrate utilization during cardiac development, mRNA levels were 
analyzed by Northern blot analysis of total RNA isolated from foetal, 
neonatal and adult Wistar Furth (WF) rat ventricles. The mRNA 
expression patterns of the rate-controlling catabolic enzyme encoding 
genes including the fatty acid utilization enzyme genes LCAS and 
medium chain acyl-CoA dehydrogenase and the gene encoding the 
glucose transporter GLUT 4 and the glycolytic enzyme encoding gene 
PFK-M were significantly upregulated at adulthood by 75 ± 3%, 95 ± 4%, 
97 ± 5%, and 70 ± 2% respectively [All p values < 0.01], compared to 
foetal expression patterns (Figure 6). The rate-controlling adult enriched 
metabolic enzyme encoding genes therefore do seem to parallel the 
enhanced energy requirements of the developing heart. Interestingly, the 
mRNA expression pattern of a "housekeeping" glycolytic enzyme encoding 
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gene, GAPDH, was not significantly regulated during cardiac development 
(Figure 6). The mRNA expression of a gene known to be more highly 
expressed in the fetal ventricle, ANF, demonstrates expected regulation 
with high expression in the foetal heart, with reducing levels into the adult 
period (p = 0.005 comparing foetal to adult expression). 
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Figure 6. mRNA levels of metabolic enzyme encoding genes in the 
developing rat heart. 
Representative Northern bioI analysis pertormed with total RNA isolated 
from lool~ 1 {oI1 .5}. noon<lto {pl . p7. p14, p21} ~nd <ldull WF mIG <lG 
described in the text. Each lane contains 20 fig total RNA. Probe 
abbreviations are described in the Methods section and under 
abbreviations. 
Effects of pressure-overload induced cardiac hypertrophy on the 
expression of fatty acid Ollidation and glycolytic enzymes encoding 
genes. 
To characterize the ellpression of genes encoding enzymes involved in 
myocardial laity aCid and glucose utilization pathways with the 
development of cardiac hypertrophy. Northern biOi studies were pertormed 
With RNA ISolated either from the right ventricles (RV) of mice subjected to 
pu lmonary artery banding (PAS) or ventricles of sham-operated controls 
After 7 days 01 pressure overload, a significant increase (p < 0.01) was 
observed in mean absolute RV weight (from 29.8 ± 0 .1 mg to 62.0 :t 3 
mg), RVitotal booy weight rat io (from 96 :t 2 to 202 ± 12 x 10~). and 
RVILV weight ratio (from 041 ± 0.01 to 0.94 :t 0.07) In the PAS group 
compared with values in controts. Levels of mRNA enco:ling the follOWing 
enzymes Involved in the myocyte fatty acid utilization pathway were 
evaluated. long-chain acyl-GoA synthetase (LGAS), the cytosolic enzyme 
that catalyzes the formation of fa tty acyl-coenzyme A thioeslers from free 
fany acids entering the cell: \he muscle isoform of camitlfl6 
palmitoy"fansferase 1 (M-GPT I). \he integral outer mltochondnal 
membrane protein that catalyzes the initial step In mitochondrial import of 
long-chain acyl-CoA, and enzymes thaI catalyze the first (LGAD and 
MGAD) and third (/ong<hain 3-0H acyl-GoA dehydrogenase or LGHAD) 
steps of the ml\ochondriall1-Ql(ldatlOl1 cycle. These enzymes are shown in 
figure 2. For companson, lORNA enco:ling the glycolytic enzyme 
glyceraldehyde-3-phospha\e dehydrogenase (GAPDH) was also 
eKamined The eKpresslOn of all FAD enzyme mRNAs' evaluated were 
Significantly lower In the hypertrophied RV than in ventricles from control 
mice (Figure 7AJ. Mean LeAS and M·CPT I mRNA levels were reduced to 
21 i 2% (p <: 0.001) and 60 i 2% (p = 0.004) of control levels. respectively 
(Figure 7B). M(tochondrlal p-ol(idation cycle enzyme mRNA levelS were 
markedly lower In the hypertrophied ventric les (LCAD mRNA levels were 
40 ± 5% of control levels. p <: 0001: medium chain acyt-CoA 
dehydrogenase mRNA levels 15 ± 2% of control, p < 0.001; and LCHAD 
mRNA tevets 23 ± 3% of controt, p < 0.001), In contrast, mean GAPDH 
mRNA tevels were 75 ± 10% higher In the pressure-overloaded RVs than 
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in controls (p = 0.01: Figures 7A and B), consistent with the known 
increase in glucose utilization in the hypertrophied heart. As expected. 
expression of atrial natriuretic factor (ANF) mRNA. a known marker for 
ventricular hypertrophy. was markedly induced in samples from 
hypertrophied RV ~-actin mRNA levels were modestly increased in the 
hypertrophied RVs compared Wi th those in controls, These results Indicate 
thai the expression of genes encoding cardiac fany acid util ization 
enzymes are coordinately repressed at the pretranslat ional level. in 
parallel With the known reduction in myocardial faUy aCid utilization dunng 
pressure overload-induced cardiac hypert rophy. Furthermore. these data 
suggest tIlat this prelranslational regulation may playa role In directing tile 
known metabOlic remodelling which occurs With Ihe development of 
cardiac hypertrophy 
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Figure 7. Expression of genes Involved in myocardial fatty acid 
utilizat ion and glycolysis parallels known changes In substrate 
p re feren ces in the hypertrophied heart. 
A Representa tive Norlhem blot analysIs obtained with total RNA Isolated 
from the RV of two mice subjected to pulmonary artery banding (PAB) Of 
from sham-operated controls (SHAM). Each lane contains 15 \Jg of Iota! 
RNA cDNA probe abbreViations are defined In the text. The 18s rRNA 
(stained with ethld,um bromide) within each lane IS shown althe bottom. 
B. Densitometric analysIs of Northern blots obtained with RNA isolated 
from the RV of six PAB or Sl)( sham-operated control mice. The bars 
represent mean (t SEM) steady-state mRNA levels (in arbitrary units or 
AU) nOfmalized to sham-operated control values (mean control value set 
at 100) The astensks denote p < 0 .01 compared with the corresponding 
COntrOl value . Abbreviabons are described in the te~t and in the 
abbreviations section on page 19 
Repression of medium chain acyl.coA dehydrogenase gene 
o ~pression during cardiac hypertrophy occurs at the transcriptional 
level through cis-ac ting sequences within the proximal promoter 
region. 
To determine whether Ihe represSIOn of medium cha,n acyl-CoA 
dehydrogenase gene expresSIOn dunng pressure overload-Induced 
cardiac hypertrophy occurs althe level of transcnptlon. PAS studies were 
repeated on mice transgenic for a 560 bp human medium chain acyl-CoA 
dehydrogenase promoter fragment fused to a chloramphenicol 
acetyltransferase reporter (MCADCAT 371) Previous studies have 
shown that the expression of MCADCAT 371 in the developing murine 
heart parallels that of the endogenous medium chain acyl-CoA 
dehydrogenase gene.aO Specifically. expression of the MCADCAT.371 
lJansgene IS Induced marKedly after birth in parallel wi th Increased 
postnatal myocardial fatty aCid utilization rates. Medium chain acyl-CoA 
dehydrogenase and CAT mRNA levels were coordinately downregulated 
in the pressure-overloaded RV compared with levels in the control group 
and compared with those in the contralateral LV within the same aOimal 
(representatIVe Northern blot shown In Figure SA). tn the right ventricular 
hyperlrophy group. mean right ventricular medium chain acyl-GoA 
dehydrogenase and CAT mRNA levels were 14 ± 2% (p < 0.001) and 22 ± 
5% (p < 0.001) of control levels, respectively (Figure 8B). Mean nght 
ventricular CAT enzyme activity In the pulmonary artery banded group 
was 22 ± 10% (p < 0.001) of corresponding control values (Figure 8B). As 
expected. RV GAPDH mRNA levels were uprcgulatcd by 73 ± 8% (p = 
0,0 1) In the PAS group In the LV. mean MCAD. CAT. and GAPDH 
mRNA levels were not significantly different in the PAB and control groups 
(Figure 8A) Similar but less pronounced results were Observed in the 
hypertrophied LV after aortiC banding (parallel experiments, data not 
shown). These results indicate that repression of medium chain acyl-CoA 
dehydrogenase expresslOI1 during cardiac hypertrophy occurs solely or in 
large part at the level of gene transcnptlon. that the cis-acting elements 
Involved in thIS transcripllonal regulatory mect1anism are located within the 
proximal medium chain acyl·CoA dehydrogenase promoter, and that the 
upstream Signalling pathway involved in th iS energy metabolic response is 
tnggered by the direct effect of the pressure overload stimulus 
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Figure 8. Expression of the MCADCAT.371 transgene Is repressed in 
the hypertrophied right ventricle. 
A. The Northern blot autoradiogram is representative of the results of PAS 
experiments performed on mice transgenic for the MCAD promoter-CAT 
reporter construct MCADCAT 371 (shown schematically in Figure 5). The 
Northern blot was obtained with total RNA isolated from LV and RV tissue 
of PAS or sham-operated control (SHAM) MCADCAT.371 mice. The bioi 
was sequentially hybridized with cDNA probes encoding mouse MCAD, 
bacterial CAT, and human GAPDH B. Expression of the MCADCAT.371 
transgcne (CAT mRNA and enzymatic activity) and endogenous mouse 
MCAD gene (MCAD mRNA) in RV of PAS or sham-operated controls 
mRNA values reprasent mean (.tSEM) levels as determined by 
densitometric analysis of RNA blots obtained with total RNA from eight 
PAS and ten control MCADCAT.371 mice from two independent 
transgenic lines [lines 10-1 (Iransgene copy number'" 55) and 10-4 
(transgene copy number = 14) described80. All values are shown relative 
to mean control values set arbitrari ly at tOO. Mean RV CAT enzymatic 
activities (normal ized to mean control levels'" 100) are also shown. The 
astensks denote a statistically significant difference (p <: 0.05) compared 
with controls. 
Characterization of the role of the NRRE-l /Site A regulatory region in 
hypertrophy induced regu lation of the medium chain acyl·CoA 
dehydrogenase gene using promoler deletional analysis. 
To explore the ro le of the NRRE·l /site A regulatory unit in the 
transcriptional repression of medium chain acyl-CoA dehydrogenase in 
response to ~enlricular pressure overload. the pulmonary ar1ery banding 
experiments were repeated with the mice transgenic for a mutant medium 
chain acyl-CoA dehydrogenase promoter in which NRRE- l was deleted 
(MCADCAT.317; see Figure 9). In striking contrast to the results with the 
MCADCAT.371 transgenic lines. the MCADCAT.317 transgene was not 
repressed in response to the pressure overload stimulus (Figure 9). 
Howeve r. because cardiac expreSSion of MCADCAT.317 was markedly 
lower compared to MCADCAT.371, these data do not definallvely 
establish a role for NRRE·l/slte A in the hypertrophic response. 
Nonetheless. these resulls do strongly suggest that the NRRE·l /Sile A 
element is required for repression of medium chain acyl-CoA 
dehydrogenase gene transcription in the pressure overloaded ventricle. 
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Figure 9. Localisation of the regulatory unit (NRRE-1 /Site A) required 
for transcriptional repression of Ihe medium chain acyl-CoA 
dehydrogenase gene in response 10 ventricular pressure-overload. 
Expression of the MCADCAT371 and MCADCAT317 transgenes (CAT 
enzymatic activity) and endogenous mouse medium chain acyl-CoA 
dehydrogenase gene (medium chain acyl-CoA dehydrogenase mRNA) In 
right ventricular hypertrophy of the pulmonary artery banded mice or 
sham-operated controls. MCADCAT.371 and MCADCAT.317 constructs in 
the transgenic mice are shown schematically under the respective dala. 
MCADCAT.371 includes a human medium chain acyl-CoA 
dehydrogenase gene promoter fragment (horizontal line) containing 371 
base pairs upstream 10 189 base pairs downstream 01 Ihe transcription 
start site (arrow) fused to a bacterial CAT gene-simian virus 40 (SV40) 
Intron-polyadenylation Signal sequence. The posit ions 01 the three known 
transcriptional regulalory units in the medium chain acyl-CoA 
dehydrogenase gene promoler are represented. Each unit is composed of 
a nuclear receptor element (NRRE-l, N2 or N3) and a GC-rich box (A, B, 
or C). The MCADCAT.317 construct is similar except lor a deletion 
disrupllon of the NRRE-l /site A unit. mRNA values represent mean (-
SEM) levels as determined by densitometric analysis of RNA blots 
obtained with lolal RNA from eight PAS and ten control MCADCAT371 
100 
!lUce and from seven PAS and seven control MCADCAT 317 mice, The 
CAT activities were measured as described in the methods section. and 
were quantnated as mean (± SEM) counts per min. All values are sho.,,1In 
as arbitrary units (AU) relallve to mean control values set at 100. The 
asterisk denote a statistically significant difference (p<O.05) compared to 
controls 
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The foetal pattem of protelnlDNA interactions is reactivated at a 
pressure overload·responsive medium chain acyl·CoA 
dehydrogenase promoter unit (NRRE-1Isite A). 
PrevIOus studies have shown thai the proKlmal medium chain acyl·CoA 
deh~rogenase promoter reglOl"l consists of three transcriptional 
regulatory uOilS. each composed of a nuclear hormone receptor response 
clement (NRRE 1, 2, or 3) Ju~taposed to a GC-rich sequence (sites A,B,or 
C) (elements shown schematically in Figure 5.19) As an Inil lal slep In the 
localization of the medium cham acyl-CoA deh~rogenase gene promoter 
pressure overload-responsive regions, electrophoretic mobility shift 
assays (EMSA) were performed with a series of probes derived from 
overlapping DNA fragments spanning the enllre proximal medium chain 
acyl·GoA dehydrogenase promoter region from bp _37 1 to bp .189 
(relative to the transcription slart site = +1 ), EMSA performed with a probe 
spanning tho NRRE-lIslle A unit (probe 371/255 which includes human 
medium chain acyl-CoA deh~rogenase gene promoter sequence from bp 
-371 10 bp ·255, see Methods) demonstrated a Significantly increased 
fnrmFilloo of DNNprolein complexes With crude nuclear orotein eKlract 
prepared from hypertrophied mouse RV samples compared to sham· 
operated control samples (data not shown). We have shown previously 
that the NRRE-11site A unit is requiroo for appropriate cardiac 
1U2 
developmental stage-speci fic expression of the MCADCAT.37t 
transgene 80 To further characterize the protein/DNA interactions at the 
NRRE-1!sile A unit, separate probes containing either the NRRE·t or slle 
A sequence were used in electromobilny shift assays As Dr. Kelly's group 
had observed previously.80 the NRRE-l probe formed two specific 
complexes (I and II) with cardiac nuclear proteins. Formallon of complex I, 
but not complex II. was increased with the nuclear extracts prepared from 
the hypertrophied ventrICle (Figure tOA, lanes 2.3). With the site A probe, 
formation of the three speCIfic oomplexes (1.11, III) with the extTaGts derived 
from hypertrophied RV was markedly Increased (Figure tOA. lanes 5·7). 
Parallel competition studies with unlabeled spe<:JflC and unrelated 
double-standed ol!gonucleolldes confirmed that complexes I and II with 
the NRRE·\ probe and complexes r to III with the si te A probe represented 
specific DNNprotein Interactions 
The eledromobilny shift assays were also peliormed with cardiac 
nuclear proteins prepared from normal embryomc day 16.5 (E t6.5) mouse 
heart 10 determine whether the hypertrophy-induced proteinJDNA 
Interactions involved reactivation of the foetal DNA binding patterns. The 
DNNprotein interaction patterns observed With the Et6.S extracts were 
nearly identical to those observed with the samples from hyper1rophled 
ventncle with either probe: bands representmg complex I (With the 
NRRE-I probe) and those representing complexes I. II, and III (With slle A) 
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were signifICantly more Intense than the corresponding bands seen With 
the control samples from adult mice (Figure lOA. lanes 3.4.7.8). These 
data suggest that repression of medium chain acyl-CoA dehydrogenase 
gene expression dunng cardiac hypertrophic growth InllOlves reactivaTIOn 
of foetal transcriptional control mechanisms at NRRE-l and sITe A. 
Members of the nuclear hormone receptor and Sp families of 
transcription factors bind the medium chain acyl-CoA 
dehydrogenase gene hypertrophy-responsivo unit. 
To identify Ihe proteins Involved in the pressure overload-induced 
Interactions at The NRRE-lIslte A unit. anlibody "supershlft" studies were 
performed PrevIOUs studies periormed in Vlfro have shown Ihat NRRE-l 
IS a pleiotropIC nuctear recepTor response element that confers 
bidirectional transcnpllonal regulabon via activator (e.g .. ret inoid X 
receptor a or RXRa) and repressor (COUP-TF) transcription factors.77. 78 
The actual nuclear receptors Involved in the control of medium chain acyl-
CoA dehydrogenase gene expression ill vivo are unknown. although the 
results of recent antibody supershift studies with normal adult mouse heart 
nuclear protein extract have identified COUP-TF or a closely related 
protein within complex I olthe NRRE-lIproteln interactiOn 80 The putative 
actlvator(s) In complex II remain umdenllfied EMSAs performed With 
'" 
antl-COUP·TF anllbody and the NRRE-1 probe revealed that complex I, 
but not complex It, was supershifted by the antibody (Figure 108). Thus, 
the known transcript ional repressor COUP-TF or an antlgenically related 
protein IS Indeed present within the induced complex I 
Previous m VIIrO studies have shown that Sp1 is capable of binding 
medium chain acyt--CoA dehydrogenase promoter site A 79 Accordingly. 
antlboclles to multiple members of the Sp transcription factor family were 
used In supershift studies 10 an attempt to Identify the proteins involved in 
the pressure overload-induced interactlOl1s at sile A. Complex I was 
panlally supershlfted with an antl-Sp1 antibody but nol by pre-immune 
serum (Figure l OB. lane 6). When an anti-Sp3 antibody was used. 
formation of complex I was diminished and complex II was abolished 
(FlQure lOB. lane 7). Addlbon of both anh-Spl and antl-Sp3 to the sample 
completely supershi fted oomplex I and abol$hed complex II (Figure l OB, 
lane 8). These results IIldicate thai complex I contains both Spl and Sp3. 
whereas complex II contains Sp3 only. The Sp antibodies did not 
recognize complex III. Supershlft studies With anti·Sp4 did not recognize 
any of the complexes (dala not shown) 
The identifica tion of COUP-TF as one of the candidate factors 
responsible for the downregulatlOfl of medium chain acyl-CoA 
dehydrogenase gene tnmscnption in response /0 pressure overload Is 
consis tent With its known role 8S a repressor. Dr. Kelly's group had snown 
previously that COUP-TF represses the transcnphonal activity 01 
homologous Of heterologous promoters via NRRE-l in cotranslectlon 
studies performed In several mammalian cell lines, Including hepatoma 
G2, CV· t , and NIH 3T3 cells. 77, 79 Medium chain acyl-CoA 
dehydrogenase promoter elements NRRE·2 and NRRE·3 (labeled N2 and 
N3 In FI9ure !j) also C()nfer modest transcriptional repress>Of1 by cour-
TF 79 To confirm that COUP-TF does act 10 repress medium chain acyl-
CoA dehydrogenase gene transcription in the cardiomyocyte, 
cotransfectlon experiments were performed in which pnmary rat neonatal 
cardiomyocytes were transfacted with a plasmid containing the same 560 
bp promoter fragment present in MCADCAT 371 fused to a luclferase 
reporter (MCADLuc.371) in the presence or absence of a mammalian 
expression vector containing a COUP· TF I cDNA (pCDM COUP) As 
shown In Figure 11 . cotransfection of pCDM.COUP mar1<.edly reduced 
MCADLuc.371 aC\Jvlty (to 28 i 4% of control). These resul ts are 
consistent with those of the electromobllily shi ft assays in the in vivo 
pressure overload studies described above and taken together, implicate 
COUP-TF as a repressor of medium chain acyl-CoA dehydrogenase gene 
expression during pressure overload-induced cardiac hypertrophy. 
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Figure 10. Binding of Sp proteins and COUP·TF to the medium chain 
acyl.coA dehydrogenase promoter unil NRRE·l /Site A is induced in 
response 10 pressure overload. 
(Panel A) Representative electromobility shift assays performed with site 
A and NRRE·\ probes with nuclear protein extract (e NE) prepared from 
RV 01 sham-operated control mice (e). RV subjocted 10 PAS for 7 days 
(H). and normal fetal (EI6.5) mouse heart (Fl. Specific complexes arc 
denoted by roman numerals and nonspecific interactIOns by "NS- (as 
defined by competition studies With unlabeled DNA fragments ). (Panel S) 
Antibody supershift studies perfOfmed with NRRE-l allcl site A probes and 
nuclear protein extracts prepared from the RV of the PAS mICe 
Anlobod,es (Ab) to eDUP·TF (COUP). Spl. and Sp3 were added to the 
samples in lanes 3. 6. 7. and 8. Prelmmune serum (PI) was added \0 
lanes 2 and 5 as a control Supershlfled immune complexes (IC) arc 
denoted by brackets at the nght margins. 
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Figure 11. COUP-TF represses medium chain acyl-CoA 
dehydrogenase gene promoter activity In cardlomyocy tes. 
The results of transient cardlOffiyocyte cotranslections (see Methods) are 
The \ranscnpllOnal actIVity 01 the medium chain acyl·CoA 
dehydrogenase promoter-Iuclferase reporter (MCADLuc.371) or Iuciferase 
reporter plasmid lacking the medium chain acyl-CoA dehydrogenase 
promoter [MCADLuc.(-l) is indicated by relative luciferase units (RLU) 
The bars represent mean RLU x 10l follOWing correction fOf transfectlon 
efficiency based on the activity of cotransfected RSV JIGal (see Methods) 
Addition of the COUP-TF expression vector pCDM COUP is Indicated. 
The values are replesentative of three separate expeflments 
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Nuclear levels of Sp 113 and COUP·TF parallel medium chain acyl· 
CoA dehydrogenaso promotor binding activities in developing and 
hypertrophied mouse heart. 
To detellTline whether expression of Sp1, Sp3, and COUP·TF parallel 
medium chain acyl·CoA dehydrogenase promoter bmding activities during 
cardiac hypertrophy and in the foetal heart, steady·state nuclear levels of 
Ihese transcription faciors were delineated by Western biOI analysIs. As 
shown in Figure 12, steady·state nuclear levels of Sp1 , Sp3, and 
COUP.TF are signifICantly higher in hypertrophied RV and fetal heart 
nuclear protein extracts compared to OOfmal adult conllnl RV samples. In 
contrast, levels of PPARo., an orphan nuclear receptor known to induce 
expression of FAD enzyme genes including medium cham acyl·GoA 
dehydrogenase.78, followed a reciprocal pattern. Given that the foelal 
samples represented both RV and LV tissue, the immunobJot studies were 
also performed With nuclear proteins prepared from right and left ventrldes 
of normal adult mice to address the possibility that the observed results 
were due to chamber-specifIC expression of Ihese faclors However. the 
nuclear levels of Sp1 and COUP·TF were identical in tight and left 
venlflcles These data indicate thai the nuclear expression of several Sp 
III 
and nuclear receptor transcription factors is induced to foetal levels in 
response to pressure overload of the ventricle. 
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Figure 12. Nuclear levels of Sp1 , SpJ, and COUP·TF paraliel DNA 
binding activ it ias in hypartrophied, foetal , and adu lt heart. 
A representative autoradiograph of a Western blot performed with 8 ~g of 
crude nuclear protein extract per lane. C, sham-operated control RV: H. 
RV hyportrophy G.:Jmple. F. embryonic day 165 mousa heart. Protein 
mass markers are displayed on Ihe righ t In kilodallons (kO) Purified Spl 
migrates on 50S-polyacrylamide gels as two polypepllde speaes with 
molecular masses of 95 and 105 kO due to differential phosphorylatIOn of 
a single polypeptide 111 The ant.-SpJ antiserum recognizes 97. 60. and 
58 kO polypepiJdes Only the 60 and 58 kO SpJ Signals are shown, 
although Ihe expression of the 97 kO SpJ protein was Identical to the 
pattem shown for the smaller isof()(ms (data not shown) Results with 
anll-PPARu and anll-adin antibodieS are shown for comparison 
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Characterization of the Temporal Patterns of Fatty Acid Oxidation 
mRNA Levels in the Hypertrophied and Failing SHHF Rat LV. 
The data shown aoove indicate that the medium chain acyl-CoA 
dehydrogenase gene is regulated at the transcriptIOnal level with the 
development of pressure overload-induced cardiac hypertrophy. 
Moreover, these data suggest that this transcriptional repression is due to 
the reactivation of a foetal gene regulatory prog ramme. To determine if 
this alteration in metabolic gene expression occurred in a separate model 
of cardiac hypertrophy and wi th the onsel of carUlac failure we have 
delineated the temporal patterns of FAO enzyme mRNA and protein 
expression dUring the development of pressure overload-induced carUlac 
hypertrophy and heart failure in the SHHF rat strain The SHHF tat strain 
is an established model for progressive LV hypenrophy and heart failure 
(Methods, refs.98, 112). Three age groups of SHHF rats were studied I) a 
control group of 2 month old animals without evidence of Significant 
ventl1C1Jlar hypertrophy; ii) a group of anemals With compensated LV 
hypertrophy (LVH) between ages 9-12 months. and iii) a group of rats With 
overt heart failure (HF). aged 16-20 months. Mean absolute heart weights 
and heart-to-brain weight ratkls were significantly increased in ooth the 
lVH and HF 9roups compared \0 controls (Table 2) To control for age-
J I 5 
related effects, normotensive, non-failing 2 month old and 17 month old 
Wistar-Funh (WF) rats were also studied. 
Tho levels of mRNA encoding medium chain acyl-CoA 
dehydrogenase, LCAD. and LCHAD were all marlc.edly lower In LV 
samples from the LVH and HF rats compared 10 cootrols (Figure 13A). As 
expected. expressIOn of ANF mRNA, was markedly induced In Ihe L VH 
and HF groups (Figure 13A). Mean sleady-slate medium chain acyl-COA 
dehydrogenase mRNA levels were reduced in the L VH and HF groups by 
79 i 5% (p<O.OI) and 89 i 3% (p<O.OO1), respectively (Figure 138), 
Mean LCAD mRNA levels were repressed to a similar degree In Ihe LVH 
and HF groups (Figure 138). LCHAD mRNA levels were downregulated 
by 72 i 9% In LVH (p<O 01) and 85:!: 4% in HF (p<OOOI) (Figure 128) 
Although mean mRNA levels for each enzyme were lower If! the HF group 
compared to the L VH group, the difference was not statistically significant 
Levels of mRNA encoding the glycolytic enzyme GAPDH were not 
slQmficanUy different among the three groups (Figures 13A and 8). No 
slgmficant difference was found In medium chain acyl·CoA 
dehydrogenase and GAPDH mRNA levels In the LV of 2 month old (n=4 ) 
and 17 month old (n=4) oontrol WF rats. indicating thaI age-related factors 
do not account for the reduced fatty acid p·oxidation enzyme mRNA 
expression. 
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'hbte 2. Charactcmtlc5 ufthc SHfWlMcc.j,.'· rats. 
c LVII IIF 
number 6 S 6 
Agc (months) 2 11:1:0.7 19:1:0.7 
OW (grams) 2210115 434±S' 415±9" 
HW (grams) 0.96:1:0.06 U&±0,7 ' 2.93:t0.l o" 
BrW (grams) 1.75±0.03 2.13:1:0.04 ' 2,04±0.0)· 
IIWIDW(~IO ' ) 4.4±1 8 4 .0±L2 7,0:03.1" 
IIWlDrW 0.55±0.03 0 .84:1:0.03 ' I 4 3:1:0.061.+ 
AbbrevlatlOru;: C _ contro l: LV II _ left ''''ntncular hypertrophy: 111'_ hca" fallurc; BW. 
body wClght; HW . hea" wClght: OrW - brain .... elght • p < 0.01 vs cuntrol. I p < 0,001 
vscontrol. ' p<O.OS vs. LVH 
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Figure 13. Fatty acid ~-o)(idation enzyme mRNA levers in the 
hypertrophied and fa iling left ventricle in Ican male SHHF rats. 
(Panel A) RepresentallVe Northern bioI analysIs performed wilh lolal RNA 
Isolated from the LV of SHHF rats In the control (e). LVH. or HF groups as 
descflbed in the le)(\. Each lane contains 18 )Ig 10lal RNA. The mean age 
and number of animals in each group is described In Table 2. Probe 
abbreviations are described in Methods. (Panel B) The bars represenl 
mean (i SE) steady-state mRNA levels. as delenTIined by densitometric 
analysis of Northern blots. In LV samples obtained from the control. LVH, 
and HF stages of male SHHF rats. Values shown are arbllrary Units (AU) 
normalized to control values (=100). All values were first normalized to 
the Signal obtained with an 185 rRNA probe 10 control for loading 
differences . • denoies p < 0.01 vs control value; . , denotes p < 0.001 vs 
control 
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Characterization of the Temporal Patterns of Fatty Acid Oxidation 
Enzyme Levels in the Hypertrophied and Falling SHHF Rat LV. 
Immunoblot analyses were performed with anti·medium chain acyl.CoA 
dehydrogenase antibody to determine whether the downregulated 
expression 01 medium chain acyl-CoA dehydrogenase mRNA In the L VH 
and HF stages 01 the SHHF rats was reflected at the protein tevel. In 
surprising contrast to medium chain acyl-CoA dehydrogenase mRNA 
levels. mean steady-state medium chain acyl-CoA dehydrogenase protem 
levels were not significantly different in the LVH samples compared to 
controls (Figure 14). However. medium chain acyl-CoA dehydrogenase 
mRNA and prolein levels were coordinately downregulaled 10 a simHar 
degree in Ihe HF group (Figure 14). Compared to controls. steady-state 
nwdlum cham acyl-CoA dehydrogenase protem and mRNA levels In the 
HF rats were reduced by 82 t 3% and 89 :t 3%, respectively. ,,-actin 
protein levels were nol slgnlrlC3ntly different among the three groups As 
obsmvcd With mRNA levels. medium chain acyl-CoA dehydrogenase 
protein levels wtlfe flat slyfllficanUy fJl!ft:IO..ml in lilt: 2 "tonUI uhJ ell .... 17 
month old male WF control rats (data not shown). Medium Chain acyl· 
CoA dehydrogenase enzymatic actiVitieS paralleled protein levels durmg 
the tranSition from LVH 10 HF (Figure 14). These findings identify a 
discordance between medium chain acyl-CoA dehydrogenase mRNA and 
1:1) 
protein levels during the L VH stage of this rat model and suggest that 
translational or posl-translatiooal regulatOfY mechanisms are involved In 
the maintenance of medium chain acyl-GoA dehy(lrogenase protein levels 
in oompensated ventricular hypertrophy. 
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Figure 14. Comparison of medium chain acyl-CoA dehydrogenase 
mRNA, protein and enzymatic activity levels In control, 
hypertrophied and failing SHHF rat hearts. 
Solid bars indicate steady-state MCAD mRNA levels. hatched bars MeAD 
Immunodetectable prote in levels and open bars MCAD enzymatic activity 
MCAD mRNA and Immunodetectable protein values are normalized 
(= 100) to corresponding control values. Steady-stale MCAD protein levels 
were determined by Immunoblot analysis of protein extracts prepared from 
the same ventricular samples used fOf Isolation of total RNA MACD 
mRNA and protein values represent denSltomemc analysis of the blots 
and are expressed as mean (t SE) arbitrary units (AU; left ordinate). The 
open bars represent mean (± SE) MCAD enzyme actIVity expressed as 
I.mol of OCIanoyl-CoA oxidiZed per minute per gram of wet weight (right 
ordinate. see Methods) The astensks represents a p value < 0.05 
compared to the corresponding control values The inset contains 
representallve Northern and Western bioi autoradiographs performed With 
an MCAD cDNA proDe and an anU-MCAD and anti-actin antibody, 
respectively 
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Attenuation of the Downregulatlon of Medium Chain Acyl-CoA 
Dehydrogenase mRNA Following Anti-Hypertensive Therapy in 
Spontaneously Hypertensive Rats. 
To e\laluate whether treatment 01 prossure-o\lerkJad Induced hypertrophy 
could attenuate the downregulahon of adult enriched fuel substrate 
catabOlic enzyme encoding genes. we trealed spontaneously hypertensl\lc 
rats with the lIasodllatll'9 {.t- and p-aclrenoreceptor antagonist cal"tledllol or 
lIehlcie alone supplemented diets for lour weeks. The left lIenlr/cular (LV) 
to body weight ratio of the groups are shown In Figure 15. The LV mass In 
the C3l"t1edllol treated spontaneously hypertensille rats were 16 ± 2% less 
than the lIehlclo a lono supplemented spontaneously hypertensive rats (p '" 
009). Of note in the cal"tledllOi treated group, the adult enriched metal>ollc 
enzyme gene expression patterns of LCAS, medium chain acyl-CoA 
dehydrogenase, GLUT4, and PFK-M were maintained at levels closer to 
the control WF's than to the placebo treated SHR group (Figure 16) 
Treatment of the WF control group with cal"tledilol did not significantly al ter 
l V mass nor gene expression compared to placebo treated controls (data 
oot shown) 
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The LV mass I body weight ratIO of the groups arc shown In Figure 15. 
The absolute inetease In LV weight I body weight ratIO of the 24 week old 
vehide treated spontaneously hypenensive ra ls was SO.1 ±4% greater 
than the age-matched WF controls (p"O.OI). In parallel with the low 
expression pattern demonstrated dUring neonatal cardiac development 
(Figure 5) the mRNA expression of the fatty acid utilizatIOn enzyme 
encodmg genes LCAS and MCAD; the glucose transporter GLUT4 and 
glycolytic enzyme encoding gene PFK-M were significantly reduced by :!. 
40% (p<O.05) (Figure 16) respectively in the SHR rats compared to normal 
adult WF control In additIOn. the mRNA levels of atrial natriuretic factor 
(ANF). the well characterized mar1<.er of cardiac pressure overload. were 
profoundly upregulated in the SHR's vs. the age-matched WF controls 
(data nOl shown) Consistent with the lack of cardiac developmental 
regulation of GAPDH. the expression pattern of this gene was not 
SlgnificanUy different between the normal control WF rat and hypertrophiC 
SHR ventrides. 
P = 0.01 
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Figure 15. Left ventricular to body weight ratio'S In the control. 
vehicle treated and carvedilol treatod SHR rats. 
The bars represent mean (t SEM) of the left ventricle to body weight ratio 
of the groups determined by wet welQht analysis at 24 weeks of age. 
Values shown are arbllrary units (AU) normalize<! to control values (::100) 
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Figu re 16. Metabolic enzyme mRNA levels In the normal WKY and 
hypertrophied SHR rat left ventricles. 
(Panel A) Representative Northern blot analysis performed with total RNA 
Isolated from the LV of control WF fats and from the hypertrophied LV of 
the SHRs Each lane contains 20 ~g total RNA Probe abbreviations are 
described In Methods (Panol 8) The bars represent mean (;t SEM) 
steady·state mRNA levels. as determined by densitometric analysis of 
Northern blolS. In LV samples obtained from the WF (control) and SHR 
rats Values shown are arbitrary units (AU) normalized 10 control values 
(=100) AU values were first normalized to the signal obtained With las to 
control for loading differences. 
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Characterization of Falty Acid p-oxidalion Enzyme Gene Expression 
in the Failing Human Ventricle. 
Wo then determined whether Ihe expressIon of genes encoding fatly aCId 
I)-oxidatIon cycle enzymes was regulated In the fai ling human heart. 
MCAD and LCHAD mRNA levels were analyzed by Northern blot analySIS 
using total RNA Isolated from the LV of human cardiac transplant 
reCipients with severe heart failure (idiopathic cardiomyopathy, n = 6, 
ischemiC heart d isease, n = 2) compared to age-matched normal control 
hearts (n = 5) obtained at postmortem. The clinical characteristics of the 
two groups are shown in Table 3. MCAD and LCHAD mRNA levels were 
significantly reduced In the heart failure group compared to controls 
(representatIve Northern blot autoradiograph, Figure 17A). Compared 10 
control~. maon (:!: SE) MCAD ond LCHAD mRNA lavele were reduced by 
56 ± 9% (p=O.03) and 64 :t 6% (p=O .03), respectively (Figure 178). LV 
MCAD and LCHAD mRNA levels in the subgroup of patients with 
Idiopathic cardIomyopathy (n " 6) were also sIgnIficantly reduced 
compared \0 controls (data not shown) Levels of mR NA encoding atrial 
natriuretic faclor (ANF), a known marker for ventricular hypertrophy and 
heart fa ilure (22), were markedly upregulated in the heart failure group 
compared to the controls (FIgure 17AJ. As determined by immunoblot 
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studies, LV steady-state MCAD protein levels paralleled MCAD mRNA 
levels (decreased by 42:t4%: p"'O.01) in the heart failure group compared 
to controls (Figures 17A and 16). 
To e)(clude the possibility that the downregulated expression of 
MeAD and LCHAD mRNA In the heart failure samples was due to 
cardiomyocyte dropout or to a generalized reduction In cardiac gene 
transcription. several control mRNAs were analyzed. Levels of mRNA 
encoding the cardiac-specifIC protem. cardiac troponm I, Of' 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were not different 
In Ihe heart failure group compared 10 controls (Figures t6A and 16B). 
Similarly. the levels of mRNA encoding ATP synthase subUnit e. a 
nuclear-encoded mitochondrial protein were unchanged between the two 
groups 
'" 
Table 3. Characteristics of human control subJects and cardiac 
transplant recipients. 
HEART FAltURE 
AGE SEX roo DIAGNOSIS AGE SEX NYFe EF 
lJ F T ' DC 
" 
M ,V )S, 
" " 
T 'OC 
" " 
,v ,r. 
S> 
" 
eVA ,oc 
" 
M 
'" ''"' 
" " 
eVA ,oc 
" " '" 
2~-' 
os F (VA IDe os 
" "' 
20·" 
,OC 2J 
" "' " .. 
'HD 
" 
M IV 
'" 
1110 
" " '" 
,,.. 
Age is in years. Abbreviations : COO· cause 01 death ; NYFC . New York 
Heart Association Functionat Ctass. EF • left ventricular ejectIOn fraction; T 
• trauma. eVA· cerebrovascular accident; tDC • idiopathic: dilated 
cardIOmyopathy; tHO· ischaemlc heart disease 
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Fi gure 17. FAO enzyme mRNA and protein levels in LV from falling 
human hearts. 
(Panel A) RepresentatIVe autoradlographs of Northern (top) and Western 
(bottom two panels) bioi anatYSIS performed with total RNA (18 fig) or 
protein (1 fig lotal protein) prepared from LV of two controls (e) and two 
subjects with heart failure (HF). Probe abbreviatIOns are described In 
Methods. The Western blot analysis was performed with a polyclonal an!!-
MeAD anllbody and aCIin control antibody as described m Methods 
(Panel B) The bars represent mean steady-state mRNA or protein levels 
shown as arbitrary Ul'lIts (AU), oormahzed (= 100) to controls and 
standardiZed to the Signal obtained with an 18s rRNA probe or 10 the total 
protein (MeAD PfOlein), Asterisks denote a Significant difference (p < 
005) compared to control values. 
The coordinate downregulation of fally acid p-oxidation enzyme gene 
expression in human heart failure could reflect a generalized decrease In 
expreSSion of all mitochondnal protein genes, such as mlQht occur with 
reduction of cellular mitochondrial number due to alleralions In 
mitochondrial biogenesis or turnover. As an indicator of mitochondrial 
number, a semi-quantitative analysis of mitochondrial DNA was performed 
using Southern blot analysis For these studies, total genomic DNA, 
isolated from the LV samples, was digested with the restriction 
endonuclease BamHI which cleaves the human mitochondrial genome at 
a single site. Age-matched samples from non-failing ventricle were used 
to control for the known accumulation 01 mitochondnal DNA deletions with 
aging.113 The blot was sequentially hybridized with a mitochondrial DNA-
specinc probe and a second probe that hybridizes with the nuclear gene 
encod ing GAPDH . The mitochondrial DNA signal. normalized to the 
GAPDH signal in three control samples. was not significantly different than 
that in three age-matched heart failure samples (Figure 18). These results 
and the observed lack of regulation of ATP synthase subunit e mRNA 
expression strongly suggest that the altered expression of FAO enzymes 
In the fai ling heart is not due to a decrease in cellular mitochondrial 
number. but rather reflects a pathway-specific regulatory phenomenon 
"" 
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Figura 18. Quantification of mitochondrial DNA in LV samples from 
humans wi th heart faHure compared to contro ls uSing Southern blot 
analysis. 
The Insel shows a representalive auloradiograph of a Southern bioi 
analysis performed with lotal cellular DNA isolated from LV tissue of two 
patients with idiopathic cardiomyopathy (eMP) compared to controls. The 
blots were sequentially hybridized wilh a mitochondrial genome probe 
(MITO) and with a human GAPDH probe (see Methods). The bars 
represent the mean signal intensities of the Southern blot analyses 
performed with the MITO probe. normalized to the signal obtained with 
GAPDH probe for three CMP samples (ages 51. 59 and 65 years. Table 
4) and three age·similar human control samples (ages 55. 59 and 65 
years. Table 3). The signals were quantified by laser densitometry and 
are shown as a ratio of Ihe mitochondrial DNA slgnal/GAPDH DNA signal 
In arbitrary units (AU). The difference in mean values was no! statistical ly 
significant 
Discussion 
The major findings from this body of work include: 
1 The identification of a transcriptional regulatory mechamsm involved in 
the reinduction of a foetal metabolic programme during pressure 
overload-induced cardiac hypertrophy_ 
2. The finding of discordant regulation of MCAD at the gene allCl protein 
levels during cardiac hypertrophy with a more concordant regulation 
with the development of heart failure. These data suggest a post-
translational regulatory control programme directing the steady-state 
enzyme levels of MCAD during the transition from cardiac hypertrophy 
to heart failure. 
3. The advaocement of the paradigm of the control of cardiac metabolism 
to include modulation al the level of metabolic enzyme gene regulation. 
118 
Reactivation of the foetal metabolic gene regulatory programmes 
with metabolic remodelling 
The reverSion to the foetat programme with the devetopment of cardiac 
hypertrophy is emerging as a common motif in the regulation of multiple 
cardiac enriched genes and gene products. More specifically, the re-
expression 01 foetal isolorms 01 a variety of myocardial ATP utilising 
pathway molecules, including cardiac enriched contractile and ion 
regula tory proteins has been demonstrated in cardiac hypertrophy 
(reviewed72-74). These findings suggest that activa tion of foetal gene 
regula tory programmes are likely adaptive structural and metabolic 
responses to pressure andlor volume overload in the terminally 
differentiated cardlomyocyte. The contribution of this reactivation of loetal 
gene regulation to the subsequent maladaptive cardiac failure is currently 
poorly understood. 
To begin to underntand the role 01 metabolic remodelling in the 
development of cardiac hypertrophy and in the tranSition to heart failure 
numerous investigators have begun to explore cardiac metabolism at the 
molecular level This includes the study 01 the regulation of metabolic 
enzyme encoding genes during cardiac development and with the onset of 
cardiac hypertrophy and heart failure. Firstly, the perinatal developmental 
expression pattern of fatly acid oxidation enzyme encoding genes 
including the medium chain acyl-CoA dehydrogenase gene were 
charactenzed in the heart.75 The expression patterns of Ihese genes were 
shown 10 parallel the postnatal biogenesis of mitochondna20 and the 
known developmental energy substrate SWitch from glucose to fatty aCids 
In the heart. The ontogenesis of GLUT4 and Hexokinase II (HK II - a rate-
limiting adult enriched glycolytic enzyme. which commits glucose to 
intracellular metabolism) gene expression have been similarly studied in 
the rat 52 These cardiac enriched glucose transport and glycolytic enzyme 
encoding genes show a simila r developmental pattern to medium chain 
acyl-CoA dehydrogenase gene expression with low expressWJn in the 
foe tal and neonatal periods, and maximal expression In the adult heart. In 
the pilot part of this study. we demonstrated that the expression pallem of 
the adult enriched PFK-M parallels the expresSIOn patterns 01 GLUT4 and 
HK II. Moreover, In thiS study we demonstrate that the developmental 
expression pattern of LCAS parallels thai of medium chain acyl-CoA 
dehydrogenase The lower expresSIOn levels of LCAS and MCAD at 
postnatal day 21 (p21) are consistent WIth the weaning pened and the 
trans Ilion from the consumption of milk - a h'9h.fat, low carbohydrate diet 
in the suckling perIOd to the normal chow diel . The increased expresSIOn 
patterns of GLUT4. and PFK-M in the adult heart correlate With the known 
utilization of carbohydrates by the adult hearts, especially In the post-
prandial period.14, 114 The lack of developmental regulation of GAPDH at 
the level of gene expression implies that this enzyme functions as a true 
"housekeeping gene" during cardiac development. These data suggest 
that during cardiac development, GAPDH gene expression may be 
regulated at the pre-translational level via a distinct gene regulatory 
programme compared to that of the other metabolic enzyme encoding 
genes studied. 
The developmental regulation of the enzymes controlling the major 
fuel substrates utilized by the heart, may be directed coordinately with the 
regulation of contractile and ion regulatory molecule encoding genes 
during cardiac development. These metabolic gene regulatory 
programmes therefore, putatively, match energy production in the heart 
with low expression during development correlating with the reduced heart 
work per cell volume required by the foetal contractile machinery.64 
Recently, Taegtmeyer and colleagues64 demonstrated that unloading the 
rat heart, with a subsequent reduction in energy requirement, results in the 
upregulation of foetal contractile genes (IJMHC), and a reduction in the 
levels of the adult enriched cardiac glucose transporter (GLUT 4) and in 
the adult enriched fatty acid mitochondrial import enzyme [muscle 
carnitine palmitoyltransferase I (CPT I)]. This unloaded heart model could 
equate to a "foetal-like" heart with respect to energy requirements and 
contractile load. Taken together, these data support the hypotheSiS that 
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this coordinate reactivation of the foetal gene expression pattern with 
respect to the adult enriched fatty acid and glycolytic encoding genes may 
be directed by integral and/or overlapping gene regulatory programmes. 
Transcriptional Control of Medium Chain Acyl·CoA Dehydrogenase 
Gene Regulation During Pressure Overload·lnduced Cardiac 
Hypertrophy 
To begin to explore this metabolic remodelling at the gene regulatory level 
we focussed on the regulatory control of the gene encoding medium chain 
Acyl-CoA dehydrogenase, which catalyzes the first step in the 
mitochondrial ~-oxidation cycle. In these studies we have demonstrated 
that the medium chain acyl-CoA dehydrogenase gene is repressed in 
response to pressure overload through reactivation of foetal 
transcriptional control mechanisms. 
Previous studies have shown that expression of the transcription 
factors c-Fos and c-Jun are induced as an immediate early response to 
ventricular pressure overload,71, 115, 116 Cl1-adrenergic agonist-induced 
hypertrophy,117 or cardiomyocyte stretch.118 Our data identify two 
groups of transcription factors involved in the development of the 
hypertrophic response. To our knowledge this was the first report of a cis-
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acting hypertrophy-responsive element and corresponding trans-acting 
regulatory proteins in an in vivo preparation of ventricular pressure 
overload. 109 We show that COUP-TF/EAR-3 interacts with the cis-acting 
element NRRE-1/site A to repress medium chain acyl-CoA 
dehydrogenase gene transcription during cardiac hypertrophic growth. 
We also demonstrate that binding of Sp1 and Sp3 to site A is induced 
during cardiac hypertrophy. Although members of the Sp family may act 
as transcriptional activators, both Sp1 and Sp3 have also been shown to 
repress gene expression in a promoter context-dependent manner.119-
121 Recently, we have identified a series of Sp binding sites in the 
promoter region of the gene encoding M-CPT I which catalyzes a rate-
limiting step in mitochondrial fatty acid import.63 Accordingly, we 
hypothesize that there could be a general role for Sp proteins in the 
coordinate regulation of genes involved in cardiac fatty acid oxidation. 
Future studies will be necessary to determine whether Sp1 or Sp3 actually 
repress transcription of genes encoding medium chain acyl-CoA 
dehydrogenase and other fatty acid oxidation enzymes. Interestingly, as 
discussed below our work and others now suggest a role of the Sp3 zinc-
finger transcription factor in the pre-translational downregulation of both 
fatty acid and glycolytic metabolic enzyme encoding genes. In this study 
we have demonstrated that the molecular regulatory programme directing 
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medium chain acyl-CoA dehydrogenase gene downregulation, during 
cardiac development and with the onset of pressure overload induced 
cardiac hypertrophy is directed in part by the upregulation of the foetally 
induced transcriptional repressor Sp3.109 Moreover, Discher, et al,122 
has recently demonstrated that the overexpression of Sp3 repressed 
expression of the glycolytic enzyme encoding gene, l3-enolase. Thus, 
activation of Sp3, may repress genes encoding enzymes in two distinct 
metabolic pathways. This regulation would suggest that coordinated 
downregulation of the adult enriched metabolic enzyme encoding genes, 
during the development of cardiac hypertrophy may be via the reactivation 
of similar and or overlapping foetal molecular regulatory programmes. 
Our findings and the results of recent studies by others suggest that 
the transcriptional regulatory pathway described here is linked to other 
genes known to be regulated during cardiac hypertrophy. For example, a 
Sp1 binding site within the skeletal a-actin gene promoter is required for 
transactivation of this gene during hypertrophic growth of rat neonatal 
cardiocytes in cell culture studies.123 Thus, it is possible that Sp1 may 
function as an activator (e.g., skeletal a-actin) or repressor (e.g., medium 
chain acyl-CoA dehydrogenase) in a promoter-specific manner in 
response to upstream signals that trigger hypertrophic growth. Two recent 
reports 111, 124 indicate that nuclear receptor signaling pathways are also 
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involved in cardiac hypertrophy programmes. In these studies, the 
retinoid receptor a (RXRa) antagonized a-adrenergic agonist- or 
endothelin-mediated cardiomyocyte hypertrophy in cell culture. Dr. Kelly's 
group has shown previously that COUP-TF competes with RXRa for 
binding to NRRE-1 to repress transcription,77 It is tempting to speculate 
that COUP-TF, as a known antagonist of RXR, regulates the expression of 
many genes during cardiac hypertrophy. 
Our data do not allow us to delineate the upstream regulatory 
mechanisms involved in the induction of COUP-TF and Sp1/3 DNA 
binding activities during cardiac hypertrophy. Our immunoblotting studies 
do, however, indicate that the nuclear levels of these factors increase 
during development of hypertrophy. The mechanism involved in the 
increased nuclear levels of these factors is unknown but could involve a 
post-translational modification such as phosphorylation. The results of 
previous studies have implicated mitogen-activated phosphorylation 
events in the cardiac growth response.125, 126 Recent reports have also 
shown that several nuclear hormone receptors including the oestrogen 
receptor and orphan receptor PPARy are targets for mitogen-activated 
kinases.127 Others have shown that a DNA-dependent kinase 
phosphorylates members of the Sp family to modify DNA binding 
activities.128 We speculate that growth factor signalling pathways playa 
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role in the activation of the transcription factors described here. Future 
studies exploring the potential link between COUP-TF, Sp1/3, and 
upstream signaling pathways should prove interesting. 
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Temporal Regulation of Medium Chain Acyl·CoA Dehydrogenase 
During Cardiac Hypertrophy and the Progression to Heart Failure. 
Comparison of the temporal patterns of medium chain acyl-CoA 
dehydrogenase mRNA and protein expression during the left ventricular 
hypertrophy (LVH) and the heart failure (HF) stages in SHHF rats, 
revealed that regulation occurs at multiple levels. Most notably, medium 
chain acyl-CoA dehydrogenase mRNA levels are markedly reduced in 
LVH compared to controls whereas medium chain acyl-CoA 
dehydrogenase protein levels and enzyme activities are not significantly 
different until the HF stage. These results suggest that an independent 
regulatory mechanism increases medium chain acyl-CoA dehydrogenase 
translation or stabilises MCAD protein in compensated ventricular 
hypertrophy. The maintenance of MCAD enzyme levels despite reduced 
mRNA levels in the hypertrophied but non-failing ventricle could be due to 
the known increase in protein synthesis in the hypertrophied cardiocyte or 
may involve a gene- or metabolic pathway-specific phenomenon. 
Our present results do not distinguish between a primary role of 
decreased myocardial fatty acid oxidative capacity in promoting the 
transition from compensated ventricular hypertrophy to heart failure, and 
a secondary phenomenon. Although MCAD protein levels and enzyme 
activities are reduced in parallel with the transition to heart failure in SHHF 
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rats, these data do not establish a cause-effect relationship. However, our 
results suggest the intriguing possibility that repression of fatty acid 
oxidation enzyme expression in the hypertrophied heart becomes 
maladaptive and therefore contributes to the progression from 
compensated ventricular hypertrophy to overt heart failure. It is well 
recognized that genetic defects in almost every enzyme in the fatty acid 
oxidation pathway, including the acyl-CoA dehydrogenases, cause 
childhood cardiomyopathy and sudden death. 7, 8 One possible cause of 
heart failure in the setting of defective FAO is inadequate myocardial 
energy supply. Alternatively, fatty acid intermediates, which could be 
injurious to the sarcolemma, may accumulate in the context of diminished 
myocardial ~-oxidative capacity. In support of this latter hypothesis, long-
chain acylcarnitines have been shown to cause ventricular arrhythmias 
and cardiac dysfunction during myocardial ischemia.129 Moreover, in a 
recent study Bonnet et al130 has linked the accumulation of intermediary 
metabolites of fatty acids, such as long-chain acylcarnitines to sudden 
death or near-miss sudden death in infants with inherited defects in fatty 
acid oxidation. Furthermore, postmortem studies have revealed lipid 
droplet accumulation in the myocardium of humans with dilated 
cardiomyopathy.131 Future studies, including delineation of the temporal 
pattern of the reduction of ~-oxidative flux during the transition from 
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cardiac hypertrophy to failure, will be useful in determining the role of 
altered fatty acid oxidation as a causal factor in the development of heart 
failure. 
Attenuation of Left Ventricular Hypertrophy with Carvedilol 
Treatment Diminishes the Downregulation of Metabolic Enzyme 
Gene Expression Patterns 
Carvedilol treated spontaneously hypertensive rats have a reduction in 
blood pressure and an attenuation in the development of cardiac 
hypertrophy.101 We therefore used these rats to evaluate whether the 
prevention of the development of cardiac hypertrophy could attenuate 
metabolic remodelling at the level of gene expression. Using the same 
dosing and formulation of carvedilol, our data confirms a modest reduction 
in LV hypertrophy in carvedilol treated SHR rats compared to placebo 
treated controls. The relatively modest attenuation in LV hypertrophy in 
our SHR group treated with carvedilol compared to that found by Ohlstein 
et al,1 01 suggest to us that the blood pressure reduction we obtained was 
less pronounced. However, we did demonstrate that in the carvedilol 
treated SHR rats, the expression pattern of the adult-enriched metabolic 
enzyme encoding genes is maintained at near control levels, compared to 
their downregulation in the placebo treated hypertrophic control group. 
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Therefore, at a purely speculative level, a molecular mechanism whereby 
carvedilol may confer cardioprotective effects in heart failure 132 may be, 
in part, via preservation of the adult metabolic gene regulatory program. 
The concept of maintaining the adult gene expression pattern has been 
previously demonstrated with another class of cardioprotective drugs, i.e. 
angiotensin converting enzyme inhibitors in post-infarction myocardial 
remodeling.133 
Some reservations have been raised regarding the use of the SHR 
strain for metabolic studies as perturbations in fatty acid and glucose 
metabolism are thought to be present in the SHR rats due to the known 
insulin resistant phenotype in this rat strain.134, 135 Moreover, recent 
data suggest that the SHR rats have a genetic defect in the fatty acid 
translocator gene (also know as Cd36), which may be associated with a 
characteristic metabolic phenotype inthis strain.136 Our data, however, 
suggest that at the level of metabolic enzyme encoding gene expression, 
the levels of the enzymes we studied rather reflect the degree of 
hypertrophy in the spontaneously hypertenSive rats as opposed to the 
genetic background. It is also unlikely that the expression patterns of the 
metabolic enzyme encoding genes in the carvedilol treated rats are due to 
the metabolic effects of ~-adrenoreceptor blockade as no regulation is 
seen comparing the treated and control WF rats. Moreover, in a study of 
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normal volunteers, no change in the serum levels of glucose or free fatty 
acids were found after treatment with carvedilol for 14 days compared to 
placebo treated controls. 137 
GAPDH gene regulation during cardiac development and 
hypertrophy 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is the first energy 
harvesting enzyme in the glycolytic pathway and is often used as a 
"constitutively expressed control" in different tissues and cell types, 
including the heart. In this study, we demonstrate that GAPDH is not 
significantly regulated during rat cardiac development nor with the 
development of pressure-overload induced hypertrophy in the SHHF and 
SHR rats. These data suggest that the GAPDH gene regulatory 
programme may be distinct form that of the rate controlling glycolytic and 
fatty acid utilization enzyme encoding genes evaluated in this study. Of 
note, in the SHHF and SHR rats, the degree of hypertrophy was 
approximately a 50% increase in left ventricular mass, compared to age 
and sex matched controls. On the contrary, in the mouse pulmonary artery 
banding study where we induced a 100% increase in right ventricular 
weight, the gene expression pattern of GAPDH was significantly 
upregulated compared to sham operated controls. 1 09 Thus, we postulate 
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that the upregulation of the GAPDH gene expression pattern with 
profound right ventricular hypertrophy. may be the result of this 
'supraphysiologic' hypertrophy. resulting in a much greater energy 
demand in these hearts compared to their sham-operated control group 
and compared to the SHHF and SHR rats. An altemate but less likely 
explanation may be that there is a ventricular specific regulatory 
programme. In the mouse study we were evaluating gene regulation in 
right ventricular hypertrophy, whereas in both the rat studies we evaluated 
gene expression in left ventricular hypertrophy. A species difference is 
unlikely as we have demonstrated similar patterns of regulation of MeAD 
in left ventricular hypertrophy in mice. rats and rabbits.138 
Coordinate Downregulation of Fatty Acid Oxidation Enzyme 
Expression in Human Cardiomyopathy. 
The ability to study the molecular regulatory programmes of metabolic 
remodelling in human disease is limited by the availability of human tissue 
during cardiogenesis and during the development of cardiac disease. We 
were however fortunate to be able to obtain tissue from end stage 
cardiomyopathic patients with some control samples from the Heart 
Transplant Program at Barnes Hospital, Washington University School of 
Medicine in St. Louis, USA. RNA and protein analysis of these tissues has 
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allowed us to evaluate whether this pattern of metabolic remodelling is 
applicable to humans at the molecular level. 
Our studies of failing human heart samples indicate that expression 
of fatty acid oxidation enzymes is coordinately downregulated at the pre-
translational level in parallel with known alterations in myocardial energy 
substrate in failing human ventricles. The reduced MCAD protein levels 
and enzyme activity in the cardiomyopathy subjects compared to controls 
parallel those found in the SHHF rat. It appears that similar translational or 
post-translational regulatory programme are activated in both humans and 
in this rat model of cardiomyopathy. 
A model of fatty acid oxidation enzyme gene regulation during the 
development of cardiac hypertrophy and the progression to heart 
failure. 
In this dissertation, I have described our recent studies in which we have 
identified a metabolic gene regulatory programme that is initially activated 
during cardiac hypertrophic growth. Transcription of the medium chain 
acyl-CoA dehydrogenase gene is repressed during the development of 
pressure-overload hypertrophy. This transcriptional repression involves re-
activation of foetal transcriptional control by the transcription factors 
COUP-TF, Sp1 and Sp3. However, as demonstrated by the studies of the 
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SHHF rat, during the early stages of hypertrophy, the levels of MCAD 
protein are maintained despite a drop in mRNA levels. The mechanisms of 
this post-transcripitonal control are unclear but likely involve control at the 
translational or post-translational levels. Moreover, in the carvedilol treated 
SH R rats we have demonstrated that this downregulation of the medium 
chain acyl-CoA dehydrogenase gene expression may be attenuated by 
blocking the development of pressure overload-induced hypertrophy. 
Finally, during the transition to overt heart failure, medium chain acyl-CoA 
dehydrogenase enzyme levels drop and, as demonstrated by others, 
myocardial fatty acid utilization may fall. This scheme is summarised in 
Figure 19. The studies included in this disseratation have not established 
a causal relationship between the reduction of cardiac fatty acid oxidation 
rates and the development of heart failure. However, the occurrence of 
heart failure in individuals with inborn errors in fatty acid oxidation 
enzymes suggests that this reduced capacity for myocardial fatty acid 
utilisation may indeed cause cardiac dysfunction. Accordingly, this 
metabolic regulatory pathway represents a useful target for future 
experimental studies aimed at the characterisation of the role of 
alterations in cellular lipid metabolism in the genesis of heart failure. 
Studies in which this gene regulatory pathway is altered by transgenesis 
or targeted gene disruption are presently underway. 
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Figure 19. Scheme for the regulation of MeAD expression 
and energy substrate switches during development of 
pressure overload-induced heart failure. 
Molecular regulation • expanding the paradigm of metabolic control 
in the heart during health and disease. 
Historically, interest in glucose metabolism dates back to 1907 when 
Locke and Rosenheim 139 described glucose uptake in the Langendorff 
isolated heart preparation. In the following decade numerous investigators 
discovered that fatty acids and glucose constitute the major cardiac 
substrates (Reviewed140). In the eal1y 1950's Bing suggested that energy 
substrate used by the heart was dependent on the blood levels of these 
major fuels and on the corresponding levels of insulin.13 The biochemical 
concept of rate-limiting enzymes in energy metabolism was introduced at 
the end of the fifth decade and extensively studied in the heart by the likes 
of Randle, Morgan, Neely and others (Reviewed140). Thus during the last 
few decades the intricate biochemical regulation of cardiac metabolism 
has been delineated (Reviewed14, 59, 114). The regulation of metabolism 
at the genomic level is, however, a more recent advance. This advance 
has followed on the sequencing of metabolic enzyme encoding genes 
during the last ten to fifteen years. In this latter era, we and others have 
begun to describe the differential expression patterns of these genes 
during in the normal and diseased heart (e.g.35, 75, 104, 122). In this 
body of work. we have taken this concept a step further, in that we have 
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identified a pressure-overload responsive regulatory unit within the 
promoter region of a metabolic gene. These data demonstrate a direct link 
between the genomic regulation of a metabolic enzyme encoding gene 
with a pathophysiologic stress on the heart. Future work in this arena will 
enable investigators to increase our understanding of how disease states 
can dictate substrate metabolism in the heart. 
Conclusion 
In conclusion, we have demonstrated coordinate and parallel pre-
translational regulation of genes encoding enzymes directing the two 
dominant metabolic fuel substrate utilization pathways during cardiac 
development and with the onset of cardiac hypertrophy. We have 
identified a gene regulatory mechanism involved in the energy substrate 
switch using the regulation of the medium chain acyl-CoA dehydrogenase 
gene as the model system. This mechanism involves, in part, the 
reactivation of foetal transcriptional control via members of the Sp and 
COUP-TF/EAR-3 families of transcription factors. These data and the 
results of previous studies suggest that this regulatory pathway is linked to 
other genes regulated during hypertrophic growth of the cardiac myocyte. 
Futhermore, in this study we have identified a putative post-
translational regulatory programme which may direct the switch in energy 
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metabolism between the 'compensated' hypertrophied heart and the 
'decompensated' failing heart. However. this concept requires additional 
investigation to clarify the mechanims of this control. 
Finally, we believe that the data obtained from these studies has 
played a significant role in advancing the concept of genomic control in the 
regulation of metabolism in the heart. 
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Appendix 
Modified Lowry Reagents 
CTC reagent (Copoer-Tartarate-Carbonate) 
20 gms Na2C03 dissolved in 100 ml's OW (distilled water) 
0.2 gms CuS04.5H20 and 0.4 gms K2 tartarate in 100 ml's OW. 
Reagent A: 
Equal volumes of CTC, 10% (w/v) Sodium Lauryl Sulfate, 0.8 N NaOH 
and OW. 
Reagent B: 
0.33 N Folin reagent (20mls of 2 N Folin-Ciocalteu reagent (Sigma 
chemicals) 
Western Blot Reagents/Solutions 
For use on the mini-protean electrophoresis rig - BioRad 
Separating Gel Solution (e.g of 7.5% gel) 
5 ml 30% Acrylamidel 0.8% Bis 
5 ml 1.5M Tris-HCI, O.4%SOS, pH 8.8 
10 ml deionised OW 
100 fll105 APS 
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20 J.11 TEMEO 
Stacking Gel 
3 ml 0.5M Tris-HCI, 0.4% SOS, pH 6.8 
1.6mls 30% Acrylamide I 0.8% Bis 
7.2 ml Oeionised OW 
60 J.1110% APS 
12 J.11 TEMEO 
Electrophoresis Gel Running Buffer 
10 X Buffer 
0.25M Tris-HCI, 1.9M Glycine, 1 %SOS, pH 8.6. 
Protein Reducing Buffer 
1 ml 0.5M Tris-HCL pH 6.8 
1m110% SOS 
1 ml Glycerol 
250J.11 0.025 Bromophenol Blue 
0.1 ml J3-mercaptoethanol 
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